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Zusammenfassung 
 
Infektionen mit dem humanen Cytomegalievirus (HCMV) können bei immungeschwächten 
Personen zu schweren Erkrankungen führen. Sie sind zudem die häufigste Ursache für 
Missbildungen nach intrauterinen Virusinfektionen. Der Zelltropismus von Herpesviren wird 
durch gH/gL Glykoproteinkomplexe in der Virushülle bestimmt. Diese gH/gL Komplexe 
vermitteln über Erkennung und Bindung zellulärer Rezeptoren und über Vermittlung der 
Fusion der Virushülle mit der Zellmembran den Eintritt des Virus in die Wirtszelle. HCMV 
kodiert für zwei alternative gH/gL Komplexe, gH/gL/gO und gH/gL/pUL(128,130,131a), 
welche beide den breiten Zelltropismus von HCMV definieren. Die entsprechenden 
Wirtszellrezeptoren wurden jedoch noch nicht identifiziert. 
 
Ziel dieser Arbeit war es, den zellulären Rezeptor des HCMV gH/gL/gO Komplexes zu 
identifizieren. Während nach Infektionen mit Wildtyp-HCMV in Zellkultur reichlich infektiöse 
Viruspartikel in den Überstand abgeben werden, produzieren Mutanten, die keinen 
gH/gL/gO Komplex haben, kaum infektiöse Viren und breiten sich vorweigend zellassoziiert 
aus. In der vorliegenden Arbeit konnte über die Untersuchung der Bindung von HCMV 
Partikeln und rekombinantem gO-IgG Fc Fusionsprotein an Fibroblasten der "platelet-
derived growth factor receptor-α" (PDGFRα) als Rezeptor des gH/gL/gO Komplexes von 
HCMV identifiziert werden. Ausschließlich gH/gL/gO-positive Viren infizieren Zellen 
PDGFRα-abhängig: i) Löslicher PDGFRα und dessen natürlicher Ligand PDGF-BB konnten 
eine Infektion mit Wildtypvirus hemmen, nicht aber Infektionen mit gO-Deletionsmutanten. 
ii) Eine Überexpression von PDGFRα in Zellen verstärkte die Infektion mit Wildtypvirus, 
nicht jedoch die Infektion mit einer gO-Deletionsmutante. Zusätzlich konnte gezeigt werden, 
dass vor allem die Infektion von PDGFRα-positiven Zellen mit freien Viruspartikeln, nicht 
aber die zellassoziierte Virusausbreitung, über die Interaktion von gH/gL/gO mit PDGFRα 
erfolgt. Die gH/gL/gO–PDGFRα Interaktion könnte damit in vivo hauptverantwortlich für die 
effiziente Infektion von ersten Zielzellen sein und stellt somit ein bedeutendes Angriffsziel 
für das Design von HCMV-Vakzinen oder neuen Therapeutika zur Behandlung von HCMV 
Primärinfektionen dar. 
 
Die Infektion der Maus mit dem murinen Cytomegalievirus (MCMV) wird seit langem als 
Model für HCMV Infektionen genutzt. MCMV besitzt wie HCMV einen gH/gL/gO Komplex. 
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MCMV gO-Deletionsmutanten zeigen einen den HCMV gO-Deletionsmutanten 
vergleichbaren Phänotyp. Hier konnte gezeigt werden, dass die Deletion von gO bei MCMV 
und HCMV den Tropismus der Viren für verschiedene Zelltypen verschiebt. MCMV Partikel 
zeigten wie HCMV Partikel, die von unterschiedlichen Zelltypen produziert werden, einen 
unterschiedlichen Zelltropismus. Das könnte darauf zurückzuführen sein, dass in 
verschiedenen Zelltypen mehr oder weniger gH/gL/gO-Komplexe in die Viruspartikel 
eingebaut werden. Aufgrund der vergleichbaren Phänotypen von HCMV und MCMV gO-
Mutanten in Zellkultur ist die Infektion der Maus ein geeignetes Tiermodell, die Rolle des 
gH/gL/gO Komplexes in vivo zu untersuchen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 	
     3 
Summary 
 
Human cytomegalovirus (HCMV) infection is a major cause of morbidity and mortality in 
immunocompromised individuals and a leading cause of birth defects after congenital 
infection. Herpesvirus cell tropism is determined by gH/gL glycoprotein complexes in the 
viral envelope. The gH/gL complexes mediate virus entry into host cells through binding to 
host cell receptors and promote fusion of viral envelopes with cellular membranes. HCMV 
encodes two alternative gH/gL complexes, gH/gL/gO and gH/gL/pUL (128, 130, 131a) 
which both shape the broad cell tropism of HCMV. However, their respective host cell 
receptors have not been identified. 
 
HCMV shows a broad cell tropism and readily produces infectious supernatant virus in cell 
culture. HCMV lacking the gH/gL/gO complex hardly produces infectious virus and spreads 
mainly cell-associated. By studying the binding of HCMV particles and recombinant gO-IgG 
Fc fusion proteins to fibroblasts, platelet-derived growth factor receptor-α (PDGFRα) could 
be identified as an HCMV entry receptor recognized by the gH/gL/gO complex. It could be 
shown that only gH/gL/gO-positive HCMV infects cells in a PDGFRα-dependent manner: i) 
Soluble PDGFRα receptor and the natural ligand PDGF-BB could inhibit infection with 
wildtype virus, but not infection with gO-knockout mutants. ii) Overexpression of PDGFRα 
enhanced infection with wildtype virus, but not infection with gO-knockout virus. It could 
also be shown that infection of PDGFRα-positive cells is up to 98% driven by the gH/gL/gO 
complex. This might indicate that, PDGFRα expression levels secure effective infection of 
first target cells. The PDGFRα - gH/gL/gO interaction may thus be an important target for 
the design of anti-HCMV vaccines or new anti-HCMV drugs to prevent primary infection. 
 
Infection of mice with murine cytomegalovirus (MCMV) has been extensively used as a 
model to study HCMV infection in vivo. It has been shown before that MCMV also 
expresses a gH/gL/gO complex which, when knocked out, exhibits a phenotype in cell 
culture comparable to gO-knockout mutants of HCMV. Here, it could be shown that gO-
knockout mutants of MCMV and HCMV show similar shifts in infection capacities for 
different cell types. MCMV progenies derived from different cell types differ like HCMV 
progenies derived from different cell types in their cell tropism. This is very likely due to cell 
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type-dependent incorporation of more or less gH/gL/gO complexes. This makes the MCMV 
infection of mice a good model to study the role of the gH/gL/gO complex in vivo. 
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1 Introduction 
 
1.1 The family of herpesviridae  
Herpesviruses are large, enveloped DNA viruses with double-stranded linear DNA 
genomes. The characteristic virion of a herpesvirus (Figure 1) is composed of an 
icosahedral capsid harboring the viral DNA, surrounded by a protein layer called tegument, 
and enclosed by an envelope consisting of a lipid bilayer containing different glycoproteins. 
After primary infection, all herpesviruses persist lifelong in their hosts by establishing a 
latent infection interrupted by recurrent reactivations. Based on the genomic organization, 
sequence homologies, and biological properties, the family of Herpesviridae is divided into 
three subfamilies; α-herpesviruses, β-herpesviruses and γ-herpesviruses. To date, more 
than 200 herpesviruses have been identified in vertebrates, including eight human 
herpesviruses: herpes simplex virus type 1 and 2 (HSV-1, -2) and varicella-zoster virus 
(VZV), which belong to the α-herpesvirus subfamily; human cytomegalovirus (HCMV), 
HHV-6 and HHV-7, which belong to the β-herpesvirus subfamily; and Epstein-Barr virus 
(EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), which belong to the γ-
herpesvirus subfamily. 
 
 
 
Figure 1: Structure of an HCMV virion. (Adapted from http://people.virginia.edu/~jcb2g/background_hsv1_ 
structure.html) 
Shown are electron microscope image of a negatively stained HCMV virion (left) and a schematic 
representation of the virion structure (right). 
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1.2 Human Cytomegalovirus (HCMV) 
HCMV, also referred to as human herpesvirus 5 (HHV-5) [1], is a human herpesvirus which 
is spread worldwide. It was first isolated and cultivated in 1956 [2, 3]. HCMV infection of 
cells leads to swelling and enlargement of the cells, a phenomenon named cytomegaly, 
which gave HCMV its name [4]. 
 
1.2.1 HCMV infection and diseases 
HCMV seroprevalence ranges from 45 to 100%, depending on geographical locations and 
socioeconomic status [5]. Transmission of HCMV occurs through different routes, either 
horizontally via direct contact with infected individuals who excrete infectious virus in their 
bodily secretions including respiratory droplets, blood, urine and breast milk [6] or vertically 
from mother to infant. The majority of HCMV infections in normal immunocompetent 
individuals are asymptomatic. However, HCMV infection of immunocompromised 
individuals (for example, patients with acquired immunodeficiency syndrome (AIDS) or 
transplant patients) results in significant morbidity and mortality. These patients show 
HCMV-associated diseases like hepatitis, pneumonia, encephalitis, retinitis, gastrointestinal 
disease and transplant rejection [7, 8]. Primary HCMV infection of mothers during 
pregnancy can result in infection of the unborn child and lead to birth defects in 0.2% to 
2.5% of all births [9]. Typical symptoms of a congenital infection are cerebral injuries 
resulting in severe developmental defects and hearing loss [9]. Associations of HCMV 
infection with the development of glioblastoma [10] and atherosclerosis [11] are also 
discussed. However, it is unknown whether HCMV is the cause of those diseases or 
whether cells in glioblastoma or atherosclerotic lesions are preferred targets for HCMV. 
 
1.2.2 HCMV therapy and HCMV vaccines 
Despite decades of the research dedicated to prevent HCMV infection, there is currently no 
authorized vaccine against HCMV.  
 
There are five antiviral drugs licensed by the FDA and the European Medicines Agency 
(EMA) to treat HCMV diseases in immunocompromised patients: Ganciclovir, Foscarnet, 
Cidofovir, Valganciclovir, and Fomivirsen. The former four drugs target the viral DNA 
polymerase to exert their antiviral action while Fomivirsen blocks an immediate early gene 
of HCMV [12]. All of these antiviral drugs have been shown to reduce HCMV infection and 
control related diseases in immunocompromised patients [13]. However, they have 
 Introduction  
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limitations such as significant side effects [14] and development of resistance [15]. 
Moreover, due to teratogenicity, they cannot be used to treat congenital infections. Thus, 
there is a strong need for developing new drugs which target other steps in viral replication, 
such as attachment and entry [12].  
 
The neurodevelopmental disabilities of children caused by congenital HCMV infection 
cause high economic costs in many countries. To eliminate congenital HCMV infection and 
eradicate HCMV from the human population, vaccination would be a priority. During the last 
decades, researchers have attempted different strategies to develop vaccines against 
HCMV, such as live attenuated vaccines (e.g. laboratory-adapted HCMV strains AD169 and 
Towne), recombinant chimeric vaccines (e.g. Towne/Toledo chimeric vaccines) and subunit 
vaccines (e.g. glycoprotein B and tegument protein pp65 vaccines) [16]. However, none 
exhibited effective protection, thus, to date, there is no licensed HCMV vaccine available. 
The lack of specific and effective treatments for HCMV infection and disease highlights the 
need for a thorough understanding of HCMV-host cell interactions, including HCMV entry 
into host cells and host immune responses against HCMV.  
 
1.2.3 HCMV genome 
The HCMV genome is the largest herpesvirus genome with a size of approximately 235 kbp 
comprising up to 250 opening reading frames (ORFs) [17]. It can be divided into two 
segments, named unique long (UL) and unique short (US) regions which are flanked by 
terminal repeats (TR) and internal repeats (IR) (Figure 2) [18]. ORFs located in the UL 
region and US region are named according to their positions. 
 
Figure 2: Schematic map of the HCMV genome. 
The HCMV genome contains a unique long (UL) and a unique short (US) region which are flanked by inverted 
repeats: 1) terminal repeat long (TRL) and internal repeat long (IRL); 2) terminal repeat short (TRS) and 
internal repeat short (IRS). 
 
To date, over 70 viral proteins have been identified in purified virions [19]. Only ~50 
proteins are thought to be essential for viral replication, and the vast majority of HCMV 
proteins interfere with cellular signals resulting in host immunomodulation [17]. 
TRL IRL
IRS TRS
UL US
20 40 60 80 100 120 140 160 180 200 220 (kb)
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1.2.4 Replication cycle of HCMV 
HCMV showes the typical replication cycle of herpesviruses (Figure 3). To infect a cell, the 
virus first penetrates the host cell membrane either through direct fusion at the plasma-
membrane or in endocytic vesicles [20-22]. Following fusion, the viral nucleocapsid together 
with the tegument is released into the cytoplasm and transported to the nucleus via 
microtubules [23, 24]. The viral genome is released into the nucleus where the viral gene 
expression starts in a temporal cascade comprising three main phases: immediate early 
(IE), early (E), and late (L) phase [25]. IE-proteins, (i.e. IE-1 and IE-2) are the first viral 
genes transcribed. Their transcription does not require replication of viral DNA or de novo 
viral protein synthesis. They mainly function as transcriptional activators to promote the 
expression of viral and cellular genes, including viral early genes. Expression of early genes 
requires prior synthesis of IE proteins. Early proteins promote viral DNA replication, which 
starts around 24 h post infection (p.i.). Following replication of the viral genome, late genes 
which code for capsid components, tegument proteins, and envelope glycoproteins are 
expressed and then assembled into progeny virions. The detailed mechanism of virion 
assembly and egress is not well-defined. In the nucleus, viral genomes are packaged into 
the capsids. These nucleocapsids undergo a primary tegumentation and an initial 
envelopment step by budding through the inner nuclear membrane into perinuclear 
cisternae, followed by a de-envelopment by fusion with the outer nuclear membrane, 
resulting in the release of the nucleocapsids into the cytoplasm [26]. Tegumentation and 
secondary envelopment occur within a cytoplasmic compartment termed the trans-Golgi 
network possessing mature forms of viral glycoproteins [27, 28]. Assembled mature virions, 
as well as other non-infectious particles (e.g. dense bodies [29]) are transported by virus 
secretory vesicles to the plasma membrane and released into the extracellular space of the 
infected cells. 
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Figure 3: Overview of the HCMV life cycle in a human cell. (Repinted from [30]) 
(A) Virus enters the host cell through interaction with cell surface receptors. Capsid and tegument proteins are 
transferred to the cytoplasm. (B) Capsids are delivered to the nuclear pore, where the DNA is penetrated and 
circularized. Tegument proteins initiate the expression of viral immediate early (IE) genes which then induce 
the expression of early (E) genes. Early proteins promote viral genome replication and late gene expression. 
(C) Late protein initiates virion assembly, including assembling of nucleocapsid in the nucleus and 
tegumentation and envelopment in the viral assembly complex (AC) (D) Infectious virus and non-infectious 
dense bodies are released from cytoplasma. 
 
1.3 HCMV cell tropism 
HCMV infects a broad range of cell types in many different organs [31], including neuronal 
cells in the brain and retina [32], fibroblasts, epithelial and endothelial cells (EC) in lung and 
gastrointestinal tract [33], hepatocytes in the liver [34] and peripheral blood mononuclear 
lymphocytes (PBML) [35]. Several cell types are considered to be responsible for HCMV 
dissemination. Circulating infected monocytes may release infectious virus within target 
organs upon differentiation into tissue macrophages [36]. Productive infection in EC of the 
blood vessels may lead to detachment of these cells, thus initiating hematogenous 
dissemination [37, 38]. In contrast, fibroblasts likely provide the loci for efficient production 
 Introduction  
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of HCMV, presumably contributing to the establishment of primary infection. HCMV is also 
capable of infecting different cell types in vitro. However, there are variations of virus 
productivity among the various cell types. Fibroblasts, smooth muscle cells, endothelial 
cells and epithelial cells are permissive for productive infection of HCMV [31], while poorly 
differentiated cells such as progenitor cells of the myeloid lineage restrict the replication of 
the virus [39]. Fibroblasts are the most commonly used cells for the laboratory passage of 
HCMV since virus yields are highest in this cell type [13]. Specifically, HCMV binds to 
fibroblasts with a capacity of 2500 - 3000 particles per cell [40, 41]. 
 
1.4 Entry of HCMV into different host cells 
The complex HCMV entry process consists of serial steps (Figure 4a), which involves 
multiple sequential interactions between viral envelope glycoproteins and corresponding 
proteins on the host cell surface [21, 22]. Initial attachment of HCMV virions to the surface 
of host cells is essential, but not sufficient for HCMV entry into cells. It is mediated by low-
affinity binding of the glycoprotein complex gM/gN and/or gB to cellular heparan sulfate 
proteoglycans (HSPGs) [42-44]. The docking likely enables a more stable interaction of 
other glycoproteins, for instance, gH/gL complexes, with specific cellular receptors, 
subsequently activating a direct fusion with plasma membrane or endocytosis followed by 
fusion with the endosomes (Figure 4b). 
 
Previous studies revealed that HCMV entry into fibroblasts involved direct fusion at the 
plasma membrane and is pH-independent [21]. However, a recent report showed that 
HCMV entry into fibroblasts can follow a macropinocytosis pathway [46]. HCMV entry into 
epithelial and endothelial cells has been described to follow a pH-dependent endocytosis 
pathway [22, 47]. Virus particles have been located in intracellular vesicles post-entry [47, 
48]. Based on the size of the endosomes, the endocytic pathway in these two cell types 
was suggested to be macropinocytosis [20, 47-50]. For HCMV entry into dendritic cells 
(DC), macropinocytosis was also identified as the entry pathway [51]. In contrast to HCMV 
entry into endothelial and epithelial cells, this process was shown to be pH-independent 
[51]. 
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Figure 4: Schematic of HCMV entry into host cells. (Reprinted from [45]) 
a. Two steps of HCMV entry: binding to the host cell and fusion with the cell membrane. 
b. Two entry pathways. HCMV enters cells by fusion at the plasma membrane or fusion with an endocytic 
membrane after endocytosis. 
 
 
1.5 HCMV envelope glycoproteins involved in HCMV entry 
Multiple envelope glycoproteins are implicated in the viral entry process of herpesviruses. 
For example, gB, gC, gD, gH and gL are involved in HSV entry into host cells [52]. 
gp350/220, gp42, gB, gH, and gL mediate EBV entry process [53]. For HCMV, so far 4 
envelope-embedded viral glycoproteins: gB, gH, gM and gN, and 5 envelope-associated 
glycoproteins: gL, gO, pUL128, pUL130 and pUL131a, have been described to contribute 
to HCMV entry (Figure 5). 
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Figure 5: Schematic presentation of HCMV envelope glycoproteins involved in entry. 
 
1.5.1 Glycoprotein B 
HCMV gB, encoded by the open reading frame UL55, is a type I membrane protein which 
consists of 906 amino acids [54]. It is highly N- and O-glycosylated. It possesses a large 
ectodomain, a transmembrane domain, and an intracellular domain. gB carries an ER-
signal sequence (amino acids 1 to 29), which is cleaved in the ER. The 160 kDa protein 
contains a furin cleavage site between residues 460 and 461. In HCMV infected cells, it is 
cleaved, resulting in an N-terminal product of about 116 kDa and a C-terminal product of 
about 58 kDa [55-61]. The two subunits are linked by a disulfide bond, and embedded in 
the envelope of HCMV virions in a form of trimer.[62, 63]. A recent report showed the 
crystal structure of HCMV gB exposed on the virion surface [64], which revealed that a 
large area of the protein was covered by a thick glycan layer, providing an explanation that 
only rarely neutralizing anti-gB antibodies are observed [65].  
 
HCMV gB is the most abundant viral glycoprotein in the virion envelope [19], and it is 
essential for HCMV entry into all cell types. It is currently considered to be involved in the 
initial attachment step and subsequent fusion step [66].  
 
gH
gO
gL
gH
UL128
gL
gB trimer
gM
UL131a
UL130
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gB mediates initial adsorption of HCMV to cell surfaces through heparan sulfate 
glycosaminoglycans [43, 44]. This process very likely serves a cell surface concentration of 
HCMV and promotes interactions with entry receptors. In addition, several studies reveal 
that gB is involved in fusion of the virion with the plasma membrane. For instance, co-
expression of gB and gH/gL is indispensable for cell-cell fusion of fibroblasts, epithelial cells 
and endothelial cells [67, 68]. gB has also been shown to interact with cell-surface proteins, 
like integrins [69, 70], epidermal growth factor receptor (EGFR) [71] and platelet-derived 
growth factor receptor-α (PDGFRα) [72]. However, both EGFR and PDGFRα could not be 
confirmed as entry receptors for HCMV [73, 74]. A gB deletion has been shown to be 
unable to enter host cells but entered cells expressing recombinant gB, indicating that gB 
functions as a viral fusion protein rather than a receptor binding protein [75]. 
 
1.5.2 Glycoproteins gM/gN 
The gM and gN proteins are conserved among all members of the herpesvirus family. 
HCMV gM (UL100) is a 42- to 45-kDa type III membrane protein containing 7 potential 
transmembrane domains [76]. It is a highly hydrophobic protein and is minimally 
glycosylated [76]. In contrast, gN (UL73) is a typical type I glycoprotein with low levels of 
glycosylation [77]. It has a 18-kDa polypeptide backbone and is extensively modified both 
by N-linked and O-linked carbohydrates in the presence of gM, resulting in a mature protein 
with a molecular mass of over 40 kDa in SDS-PAGE gels [77]. gN exhibits significant amino 
acid sequence variability among different HCMV strains [78]. Both gM and gN are essential 
for in vitro replication of HCMV since deletion of the C-terminal cytoplasmic tail of gM or the 
carboxy-terminal domain of gN both resulted in replication-deficient viruses [79, 80]. 
Together, gM and gN form a heterodimeric complex through disulfide bonds between 
cysteine 44 of gM and cysteine 90 in gN [77, 81]. The gM/gN complex is an abundant 
protein component of the HCMV envelope [19]. Like gB, gM/gN also binds to cell surface 
heparan sulfate glycosaminoglycans, and thus, is involved in the initial attachment of virions 
to the target cells [82]. Collectively, the HCMV gM/gN complex is an essential viral 
component which interacts with heparin sulfate glycosaminoglycans to mediate the initial 
attachment of virions to the cell surface [44, 82]. 
 
1.5.3 gH/gL glycoprotein complexes 
The gH/gL complex of herpesvirus plays a core role in mediating virus entry through 
interactions with cellular receptors and the fusion protein gB. HCMV gH (UL75), an N-
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glycosylated 86 kDa type 1 transmembrane protein, is linked to the 34 kDa gL (UL115) via 
a disulfide bond to form a stable heterodimeric complex which is indispensable for HCMV 
entry. Both gH and gL null mutants are defective for entry [83-89]. The gH/gL heterodimer 
possesses prominent structural plasticity, suggesting that gH/gL may trigger entry signals 
via interacting with various molecules on the cell surface and activate the highly conserved 
fusion protein gB [90]. It has been shown that viral particles lacking gH/gL cannot enter 
cells expressing gH/gL [75], indicating that the gH/gL complexes function as binding 
partners of entry receptor rather than simply being fusion triggers. gO and UL128 mutually 
exclusively bind the same site on gL via a disulfide bond and form two alternative gH/gL 
complexes: gH/gL/gO [91, 92] and gH/gL/pUL(128, 130, 131a) [93, 94]，which are 
suggested to play key roles in recognizing cellular receptors of HCMV and determine the 
HCMV cell tropism [48, 65, 93-95] (Figure 6). The relative amounts of the two gH/gL 
complexes in virion envelopes are highly relevant to viral entry [50]. To date, it is largely 
unknown how gH/gL interacts with receptor-binding glycoproteins or molecules on the cell 
surface and how it activates gB. 
 
 
Figure 6: Schematic presentation of HCMV’s mutually exclusive gH/gL complexes. (Reprinted from [98]) 
This illustration of CMV gH/gL complexes is based on their structures [99]. Cysteines are shown as stars and 
labeled. Approximate locations and shapes of gH, gL, gO, UL128, UL130 and UL131 are shown. Membrane 
and transmembrane anchors are shown schematically. 
 
a
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1.5.3.1 gH/gL/gO 
HCMV glycoprotein O (UL74) is unique for β-herpesviruses [92]. gO possesses several 
conserved cysteines and 18 potential N-glycosylation sites and the mature form runs at 
around 125 kDa in polyacrylamide gels [92, 100]. In HCMV-infected human foreskin 
fibroblasts (HFF), gO covalently binds to gH/gL in the ER [89, 92], and is subsequently 
processed in the Golgi apparatus [89, 101]. The mature gH/gL/gO complex is about 240 
kDa, and has been proven to be incorporated into the virion envelopes in all tested HCMV 
strains [89, 102]. There are more than eight isoforms of HCMV gO with an identity of amino 
acids ranging from 70% to 90% [102]. Different gO isoforms have distinct affinities to bind 
gH/gL [102]. gO is not essential for HCMV replication [103], but the gH/gL/gO complex 
plays key roles in mediating virus entry into host cells. HCMV mutants lacking gO, or 
mutants with low amounts of gH/gL/gO in their envelopes, have been shown to be 
compromised in entry into all tested cell types, including fibroblasts, epithelial cells, EC and 
macrophages [104]. Virus particles of gO deletion mutants released from infected cells 
have much lower infections titers (<1000) than the wildtype virus. Infections with gO-
deletion mutants exhibit a cell-associated spread pattern in cell cultures [103, 105-108]. Of 
note, the supernatant-driven spread of the gO-null mutants has been shown to be severely 
impaired in fibroblasts, whereas the focal growth was not affected [106]. In particular, it has 
been shown that HCMV mutants lacking gH/gL/gO were impaired at the fusion step of entry 
into host cells, despite containing relatively more gH/gL/pUL(128, 130, 131a) [107]. Antisera 
to gO neutralized HCMV entry into fibroblasts, suggesting that gO plays a direct role in 
HCMV entry (Patent US7147861 B2, 2001). The recombinant gH/gL/gO complex interferes 
with HCMV entry into fibroblasts but not entry into other cell types, suggesting that the 
trimer may bind to a fibroblast-specific receptor [68]. What role the HCMV gH/gL/gO 
complex plays in vivo is not clear, however, a recent in vivo study of mouse CMV gH/gL 
complexes revealed that gH/gL/m74 (a functional homologous of HCMV gH/gL/gO), is 
essential for entering the first target cells including epithelial cells, EC and macrophages in 
primary infection [109]. Intriguingly, there are abundant neutralizing antibodies to gH 
detected in HCMV-serum positive individuals [110], but only one neutralizing antiserum to 
gO has been reported [92]. 
 
1.5.3.2 gH/gL/pUL(128, 130, 131a) 
It has been shown that the gene products of UL128, UL130 and UL131a bind gH/gL to form 
the alternative pentameric gH/gL complex, gH/gL/pUL(128, 130, 131a) [93]. pUL130 is a 
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35-kDa glycoprotein, and both pUL128 and pUL131a have a size of approximately 15- to 
18-kDa. The more closely characterized pUL128 has four conserved cysteine residues near 
the N-terminus which are a structural characteristic of β- (or CC-) chemokines [111]. HCMV 
strains lacking the UL128, UL130 and UL131 gene locus have lost their tropism for 
epithelial and endothelial cells [93, 112-114]. The intact pentameric complex is essential for 
mediating HCMV infection of epithelial and endothelial cells and monocyte-macrophages 
[94, 97, 115-117]. Recent studies found that recombinant gH/gL/pUL(128, 130, 131a), but 
not the gH/gL dimer, inhibited HCMV entry into epithelial cells and pUL(128, 130, 131a) are 
necessary for the interaction with cell surface receptors [118-120]. These findings suggest 
that pUL(128-131a) is essential for binding of epithelial-specific receptors. 
 
1.5.3.3 gH/gL/gO and gH/gL/pUL(128, 130, 131a) complexes shape the HCMV tropism 
gO and pUL(128, 130, 131a) form mutually exclusive complexes with gH/gL which are 
incorporated into the virions. HCMV mutants lacking gH/gL/pUL(128, 130, 131a) can 
efficiently infect fibroblasts, whereas mutants lacking gH/gL/gO are severely impaired for 
infecting all cell types [103, 107], leading to the conclusion that gH/gL/gO and 
gH/gL/pUL(128, 130, 131a) bind different cellular receptors, however, only gH/gL/gO 
maintains the general gH/gL entry functions in all cell types, such as activating gB [104]. 
 
Current studies support a model in which gH/gL/gO mediates virus entry into fibroblasts, 
while gH/gL/pUL(128, 130, 131a) mediates virus entry into epithelial cells and EC. The 
relative abundance of the trimer and pentamer may shape HCMV tropism by influencing the 
efficiencies of virus entry into different cell types. Viruses with relatively higher amounts of 
pentamer preferentially infect epithelial cells and EC whereas viruses with relatively higher 
amounts of trimer tend to enter fibroblasts [50]. 
 
Among different HCMV strains, gO varies a lot [102] while UL128, UL130 and UL131a 
genes are highly conserved [121]; therefore, the diversity of gO might affect the ratio of 
gH/gL/gO to pentamer incorporated into the virions. In accordance with this, a study found 
that gO isoforms from different HCMV strains have distinct affinities to bind gH/gL, and may 
affect the relative ratios of gH/gL/gO and gH/gL/pUL(128, 130, 131a) incorporated, thus 
contributing to their distinct cell tropism [102].  
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HCMV progenies produced from both fibroblasts and EC cultures show a distinct cell 
tropism due to the incorporation of different amounts of gH/gL/gO and gH/gL/pUL(128, 130, 
131a) complexes in their virions [122]. Fibroblast-derived virus contains both the trimer and 
pentamer, and is thus capable of infecting both fibroblasts and EC [122]. In contrast, EC- 
specifically retain EC-tropic virus with high amount of gH/gL/pUL(128, 130, 131a) complex. 
EC-released virus has relative low amount of the pentameic complex, and therefore can 
readily infect fibroblasts, but scarcely infects EC [122]. The spread-pattern of HCMV in 
fibroblast cultures is supernatant-driven whereas spread in EC cultures is cell-associated. 
 
It is commonly known that gH/gL complexes mediate entry of HCMV into host cells The 
mechanism of the cell-type dependent switch of HCMV cell tropism remains largely 
unknown, however it has been shown that the relative ratio of the alternative gH/gL 
complexes shape the cell tropism. Recent work has identified the a viral glycoprotein 
pUL148 acts as a regulator of the relative amounts of the gH/gL/gO and gH/gL/pUL(128, 
130, 131a) complexes in virions. pUL148 is capable to bind gL, thus interferes with 
incorporation of pUL128 or gO into the gH/gL dimer [123]. 
 
1.6 Cellular receptors involved in HCMV entry 
HCMV’s broad cell tropism suggests that HCMV either utilizes multiple cell type-specific 
receptors or a broadly expressed receptor or a combination of both for entry. Over the past 
two decades, many receptor candidates have been put forward. However, none of these 
molecules have been verified to be indispensable entry receptors for HCMV [50]. 
 
The first candidate shown to bind HCMV virions was β2-microglobulin [124, 125]. However, 
it has later been shown that there is no correlation between β2-microglobulin expression 
and in vitro entry or in vivo spread of HCMV [126, 127]. 
 
Annexin II expression has also been shown to promote HCMV infection by interacting with 
HCMV gB [128-132]. However, cells lacking annexin II are still fully permissive for HCMV 
entry and initiation of infection [133]. 
 
Human aminopeptidase (CD13) has also been implicated as an HCMV receptor. Only 
CD13-positive human peripheral blood mononuclear cells (PBMCs) supported productive 
HCMV infection [134-136]. Both CD13-specific antibodies and chemical inhibitors of CD13 
 Introduction  
     18 
activity inhibited HCMV binding and entry [134]. However, later reports negated CD13 as a 
receptor for HCMV based on the observations that CD13 antibodies could bind and 
neutralize virus before contact with cells and HCMV could enter CD13-depleted cells [137]. 
 
THY-1 (CD90), has recently been suggested to play a role during HCMV entry based on the 
observation of a positive correlation between HCMV infectivity and THY-1 expression 
levels, and an interaction between THY-1 and HCMV gH and gB [138]. Both HCMV gH and 
cell surface THY-1 were reported to interact with αvβ3 integrin to trigger cellular signaling, 
thus, the observed interaction between gH and THY-1 might be promoted by αvβ3 integrin 
during HCMV entry. 
 
EGFR was initially described as a ligand for gB. Upon HCMV infection, EGFR is activated 
and triggers EGFR-dependent signaling in fibroblasts, breast cancer cells and monocytes 
[71, 139, 140]. However, EGFR-negative cells, such as hematopoietic cells, can 
nevertheless be infected by HCMV. Inhibition of EGFR with antibodies or inhibitors or 
siRNAs had no effect on HCMV entry [73, 134]. 
 
Cellular integrins, α2β1 and α6β1, were reported to bind to a disintegrin-like domain of 
HCMV gB [69, 70]. Integrin signaling and HCMV entry could be inhibited by disintegrin 
domain peptides and anti-integrin antibodies [69, 70]. In addition, αvβ3 has been shown to 
interact with gH and associate with EGFR in lipid rafts to facilitate HCMV infection of 
fibroblasts [139]. Anti-integrin antibodies had no effect on HCMV attachment but specifically 
inhibited the transport of pp65 (pUL83), a virion tegument protein, suggesting that integrins 
function at a post-attachment entry step. Interestingly, EGFR can be phosphorylated by 
activation of β1, β3 and αv integrins [141, 142]. 
 
PDGFRα has initially been identified as a ligand for recombinant gB. HCMV binding to 
fibroblasts and EC has been shown to result in PDGFRα phosphorylation and activation of 
downstream molecules [72]. Based on the observation that recombinant gB can interact 
with PDGFRα and that HCMV infection can be inhibited by knockdown of PDGFRα, by the 
PDGFRα ligand PDGF-AA, by the tyrosine-kinase inhibitor Imatinib mesylate and by a 
PDGFRα-neutralizing antibody, it has been claimed that PDGFRα functions as an entry 
receptor for HCMV [72]. In contrast, a later study contested the previous claim that 
PDGFRα acts as a receptor for HCMV gB [74]. Although overexpression of PDGFRα 
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strongly enhanced HCMV infection of epithelial and endothelial cells for both wildtype 
HCMV and gH/gL/pUL(128, 130, 131a) deficient mutants, virus entry was neither affected 
by a panel of PDGFRα antibodies or PDGFRα ligand in fibroblasts, epithelial, or endothelial 
cells nor by knockdown of PDGFRα in epithelial cells [74]. 
 
In summary, currently HCMV entry receptors are still not well defined. 
 
1.7 MCMV as a model to study HCMV 
Due to the strict species specificity of HCMV, strategies designed to test anti-HCMV 
vaccines or therapies have to use appropriate animal models using closely related viruses 
[143]. Rhesus CMV infection of rhesus monkeys serves as a good model to study HCMV 
infection [144]; however, it is time-consuming, scale limited and expensive. Murine CMV 
(MCMV) is by far the most commonly used model to study CMV infection in vivo with the 
following advantages: i) HCMV and MCMV share 80 conserved ORFs [145, 146] and some 
of them can even be exchanged [147, 148]. ii) the pathology and host immune response to 
MCMV infection are similar with those of HCMV infection [149]. For instance, MCMV is also 
able to establish latent infection in immunocompetent mice [150], whereas it is lethal for 
immunosuppressed mice [151, 152]. Moreover, activation from latent infection [152-156] 
and transmission during transplantation and blood transfusion were also observed for 
MCMV [154, 157]. The MCMV model has also been used to evaluate potential antiviral 
drugs and the identification of host resistance genes. It permits the study of MCMV mutants 
in vivo [158].  
 
1.7.1 MCMV gH/gL glycoprotein complexes 
The structure of the MCMV genome is equivalent to that of HCMV. Multiple MCMV proteins 
have homologs in HCMV [159], including a number of essential proteins such as the IE-1 
protein [160, 161], the DNA polymerase [162] and some glycoproteins like gH, gL, and gB 
[163, 164]. 
 
m74 of MCMV, the positional homolog of HCMV UL74 (Figure 7), codes for a glycosylated 
protein which is found to be incorporated into the gH/gL (m75/m115) complex and 
packaged into MCMV virions [159, 165]. m74 deletion mutants of MCMV exhibit similar 
entry and spread defects as HCMV lacking gO. Virus spread shifts from supernatant-driven 
to cell-associated spread. Entry into fibroblasts shifts from energy independent and pH-
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insensitive to an energy-dependent and pH-sensitive pathway for m74 deficient mutants. 
This suggests that the MCMV m74 protein and HCMV gO possess similar functions in CMV 
entry and spread [165]. When studied in vivo, it was found that gH/gL/m74 was found to be 
critical for infection of first target cells by mediating virus entry into diverse cell types such 
as endothelial cells, liver macrophages, and hepatocytes, whereas it was dispensable for 
intra-tissue spread [109]. 
 
 
Figure 7: Schematic presentation of gene loci of the constitutions of the HCMV and MCMV gH/gL 
complexes. 
The positions of genes encoding gH, gL, gO for both viruses are indicated. The upper insert shows the loci of 
UL128, UL130 and UL131A of HCMV. The lower insert indicates the locus of m128-m133 of MCMV. Terminal 
long (TRL) and short repeats (TRS), inner long (IRL) and short (IRS) repeats are also shown for HCMV. 
Terminal repeats at both ends of the MCMV genome are indicated.  
 
For MCMV, the m131/129 (Figure 7) protein products was found to encode a protein which 
forms an alternative MCMV gH/gL complex [166]. The gene product of m131/129 is the 
MCMV MCK-2 chemokine [167, 168]. Notably, similar to the HCMV pUL128, MCMV MCK-2 
has four conserved cysteine residues near the N-terminus, which is characteristic for a CC 
chemokine. Both MCK-2 and pUL128 have been shown to be active chemokines [117, 169, 
170]. Deletion of MCK-2 reduced MCMV infection of macrophages both in cell culture and 
in vivo [109, 166, 171]. 
 
MCMV mutants lacking both m74 and MCK-2 are not able to produce infectious virus, a 
character shared by double-deficient mutants of HCMV. Accumulatively, current data 
support the concept that MCMV expresses functional homologues of gH/gL/gO and 
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gH/gL/pUL(128, 130, 131a), which also determine the entry pathways, cell tropism, and 
spread pattern. 
 
1.7.2 Cell tropism of MCMV 
Similarly to HCMV, MCMV has the capacity to infect a broad spectrum of cell types and 
tissues in vivo [172]. MCMV DNA was detected in different organs of infected mice, such as 
salivary glands, liver, kidney and lung [173, 174]. MCMV is also able to be propagated in 
vitro in many different cell types, including fibroblasts, epithelial cells, EC and macrophages 
[175, 176]. Of note, fibroblasts are the most productive cell culture system for both HCMV 
and MCMV [175, 176].  
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1.8 Objectives 
For most human herpesviruses, one or more cellular receptors have been identified, but not 
for HCMV. Numerous studies on HCMV entry have identified the alternative HCMV gH/gL 
glycoprotein complexes, gH/gL/gO and gH/gL/pUL(128, 130, 131a), as the envelope 
glycoprotein complexes recognizing cell type-specific receptors, however, their respective 
host cell receptors are still undiscovered. 
 
Objectives of this thesis were: 
1) identification and characterization of the cellular receptor of HCMV gH/gL/gO 
complex by using either recombinant gO protein or virions expressing only the 
gH/gL/gO complex; 
2) evaluation of the role of the receptor to HCMV cell tropism in cell culture; 
3) comparison of the role of HCMV and MCMV gH/gL/gO in cell tropism in vitro. 
 
Identification of cellular receptors will not only facilitate to understand the complex cell 
tropism of HCMV but also aid the development of antiviral strategies and vaccines. 
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2 Materials and Methods 
 
2.1 Materials 
 
2.1.1 Devices 
Device Company 
Centrifuges:  
Eppendorf Centrifuge 5417R Eppendorf, Hamburg, DE 
Multifuge 3 S-R Heraeus Instruments, Gera, DE 
Biofuge stratos Thermo Fisher Scientifc, Osterode, DE 
Ultracentrifuge L8-55 M Beckmann Coulter GmbH, Krefeld, DE 
Gel electrophoresis: 
Power Pac 200 Bio-Rad, Hercules, DE 
Mini-PROTEAN 3 Cell Bio-Rad, Hercules, DE 
Mini-PROTEAN Tetra System Bio-Rad, Hercules, US 
Incubators: 
HERA cell 150 (eukaryotic cell culture) Heraeus Instruments, Gera, DE 
HERA cell 150i (eukaryotic cell culture) Heraeus Instruments, Gera, DE 
CERTOMAT BS-1 (bacterial shaker) Sartorius AG, Göttingen, DE 
Microscopes: 
Axiovert 40C (light microscope) Carl Zeiss MicroImaging GmbH, Jena, DE 
Leica DMI4000 B (fluoresence microscope) Leica, Wetzlar, DE 
Pipettes: 
PIPETBOY acu pipet INTEGRA Biosciences AG, Zizers, CH 
Eppendorf® Multipette® Plus pipette Eppendorf, Wesseling, DE 
PIPETMAN Classic™: P20, P100, P200, P1000 Gilson S.A.S., VILLIERS LE BEL, FR 
Miscellaneous: 
BD FACSCanto™ II (FACS machine) BD Biosciences, San Jose, US 
Bio-Photometer Eppendorf, Hamburg, DE 
Cell culture laminar flow hood BDK, Sonnenbühl-Genkingen, DE 
CLARIOstar microplate reader (luciferase 
assay) BMG LABTECH GmbH, Ortenberg, DE 
Developing machine FPM-100A Fuji Photo Film Co., LTD, Tokyo, JP 
Gel-Doc™ 200 ( imaging of blots ) Bio-Rad, Hercules, DE 
Gel Doc™ EZ Gel Documentation System Bio-Rad, Hercules, DE 
Gene Pulser Xcell™ Electroporation Systems Bio-Rad, München, DE 
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Device Company 
HypercassetteTM Amersham life science, Buckinghamshire, UK 
MS1 Minishaker (votexing) IKA, Wllmington, NC 
NanoDrop 1000 Thermo Fisher Scientifc, Osterode, DE 
Neubauer Chamber (cell counting) Celeromics, Grenoble, FR 
Overhead shaker REAX 2 Heidolph, Schwabach, DE 
PH meter 430 Corning, NY, US 
Roller mixer SRT1 Stuart, Staffordshire, UK 
Sonifier 450 Branson, UK 
Thermomixer 5436 Eppendorf, Hamburg, DE 
Water Bath GFL Gesellschaft für Labortechnik GmbH, Burgwedel, DE 
Weighing machine KERN 470-36 KERN & Sohn GmbH, Balingen, DE 
VACUSAFE (aspiration of liquids) INTEGRA Biosciences AG, Zizers, CH 
VERSAmax microplate reader (ELISA) Molecular Devices, Sunnyvale, US 
 
2.1.2 Consumables 
Name Company 
Amicon® Ultra-15 Centrifugal Filters Merck Millipore, Darmstadt, DE 
Cell culture dishes (10 cm and 15 cm) Becton Dickinson, Heidelberg, DE 
Cell culture plates (6-, 12-, 24-, 48-, 96-well)  Becton Dickinson, Heidelberg, DE 
Combitips plus (5 ml, 10 ml) Eppendorf, Hamburg, DE  
CryoTube™ Vial Nunc, Langenselbold, DE 
Electroporation cuvettes Bio-Rad, München, DE 
Falcon conical tubes (15 ml, 50 ml)  Becton Dickinson, Heidelberg, DE 
Falcon Tubes for FACS Becton Dickinson, Heidelberg, DE 
Hybond™-N+ Nylon membrane GE Healthcare, Freiburg, DE 
Hyperfilm™ ECL™ detection film GE Healthcare, Freiburg, DE 
PCR Tubes Biozym, Hessisches Oldendorf, DE 
Pipettes (2 ml, 5 ml, 10 ml, 25 ml) Sarstedt, Nümbrecht, DE  
Pierce™ NeutrAvidin™ Coated Clear Strip Plates Thermo Fisher Scientific, Rockford, US 
Photometer cuvettes Brand, Wertheim, DE 
Safe lock tubes (0.5 ml, 1.5 ml, 2 ml)  Eppendorf, Hamburg, DE  
Screw cup tubes 1.5 ml Biozym, Hessisches Oldendorf, DE 
Ultracentrifugation tubes Beckman Coulter GmbH, Krefeld, DE 
Whatman blotting paper (0.7 mm) Macherey-Nagel, Düren, DE 
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2.1.3 Reagents  
Name Company 
Acrylamid/Bis-acrylamide 30% Solution Merck, Darmstadt, DE 
Agarose Invitrogen, Karlsruhe, DE 
APS  Sigma-Aldrich, Steinheim, DE 
Bacto™ Agar  Becton Dickinson, Heidelberg, D  
Bacto™ Tryptone  Becton Dickinson, Heidelberg, D  
Bacto™ Yeast Extract  Becton Dickinson, Heidelberg, D  
BenchMark prestained protein ladder Invitrogen, Karlsruhe, DE 
Beta-Mercaptoethanol Sigma-Aldrich, Steinheim, DE 
Coomassie Blue G-250 Sigma-Aldrich, Steinheim, DE 
BSA Sigma-Aldrich, Steinheim, DE 
cOmplete™ Protease Inhibitor Cocktail Roche, Mannheim, DE 
DMSO Merck, Darmstadt, DE 
DNA 100bp ladder and 1 kb ladder NEB, Frankfurt am Main, DE 
DTSSP (3,3'-Dithiobis (sulfosuccinimidylpropionate))  Thermo Fisher Scientific, Bonn, DE 
DTT (dithiothreitol) Roth, Karlsruhe, DE 
EDTA (ethylenediaminetetraacetic acid) Sigma-Aldrich, Steinheim, DE 
Ethisiumbromide 1%  Roth, Karlsruhe, DE 
EZ-Link Sulfo-NHS-LC-Biotin Thermo Fisher Scientific, Bonn, DE 
Glycerin Roth, Karlsruhe, DE 
Glycin Roth, Karlsruhe, DE 
imatinib mesylate Sigma-Aldrich, Steinheim, DE 
Isopropanol  Sigma-Aldrich, Steinheim, DE 
Kanamycin Sigma-Aldrich, Steinheim, DE 
Methanol Sigma-Aldrich, Steinheim, DE 
Mouse IgG Fc-PDGFRα fusion protein R&D Systems, Minneapolis, US 
Mouse IgG Fc-PDGFRβ fusion protein R&D Systems, Minneapolis, US 
NaCl (natrium chloride) Merck, Darmstadt, DE 
Ampicillin Invitrogen, Karlsruhe, DE 
PFA (Paraformaldehyde) Merck, Darmstadt, DE 
Polyethylenimine Sigma-Aldrich, Steinheim, DE 
Ponceau S solution Sigma-Aldrich, Steinheim, DE 
Protein A IgG Binding and Elution Buffers Thermo Fisher Scientific, Bonn, DE 
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Name Company 
Protein A sepharose beads GE Healthcare, Freiburg, DE 
Restore™ Western blot Stripping Buffer Thermo Fisher Scientific, Bonn, DE 
SDS  Merck, Darmstadt, DE 
Skimmed milk powder Merck, Darmstadt, DE 
TEMED  Roth, Karlsruhe, DE 
Tris-Base Sigma-Aldrich, Steinheim, DE 
Triton X-100 Sigma-Aldrich, Steinheim, DE 
Trypan blue 0,5% (w/v) Biochrom KG, Berlin, DE 
Tween 20 Sigma-Aldrich, Steinheim, DE 
Versene Solution Thermo Fisher Scientific, Bonn, DE 
Zeocin™ Thermo Fisher Scientific, Bonn, DE 
crystal violet Sigma-Aldrich, Steinheim, DE 
 
2.1.4 Commercial kits 
Name Company 
Expand High Fidelity PCR system Roche, Mannheim, DE 
EZ-Link™Sulfo-NHS-Biotinylation Kit Thermo Fisher Scientific, Bonn, DE 
FireSilver Staining Kit Proteome factory, Berlin, DE 
FuGENE HD Transfection Reagent Roche, Mannheim, DE 
illustraTM plsamidPrep Mini Spin Kit GE Healthcare, Freiburg, DE 
Luciferase Reporter Assay Kit I (Firefly) PromoKine, Heidelberg, DE 
Nucleobond® PC100 Kit Macherey-Nagel, Düren, DE 
Pierce™ ECL Plus Western blotting Substrate Thermo Fisher Scientific, Rockford, US 
QIAquick® Gel Extraction-Kit Qiagen, Hilden, DE 
 
2.1.5 Enzymes  
All restriction endonucleases and enzymes for DNA analysis were purchased from NEB, 
Frankfurt am Main, DE and and applied according to the manufacturers' instructions. 
 
2.1.6 Primers 
Primers were synthesized by Metabion (Martinsried, DE). 
 
 
 
Materials and Methods 
     27 
 
Primers for cloning HCMV gO 
Name Sequence (5' to 3') Restriction site 
forward ATAACCATGGGTAAGGTCGTTAGACCACCGG Nco I 
reverse CAGAAGATCTCTGCAACCACCACCAAAGGC Bgl II 
 
Primers for sequencing cloned gO 
Name Sequence (5' to 3') 
forward TCTGTTCTGCGCCGTTACAG 
reverse AGGAGCTGGGCATTTGTGAC 
 
2.1.7 Plasmids 
pFUSE_mIgG2B_Fc2 (Cat. No. pfuse-mg2bfc2, InvivoGen): An eukaryotic expression 
vector for cloning and expressing of Fc-fusion proteins. The vector expresses the hinge 
region and the Fc region of the murine IgG2b heavy chain. The flexible hinge region allows 
each part of the fusion protein to function independently. It also expresses the IL-2 signal 
sequence for secretion of the Fc-fusion proteins. 
 
pCMV-PDGFRα (Cat. No. HG10556-UT, Sino Biological Inc.): The pCMV3 vector (6223bp) 
expresses the full length (3270bp) cDNA of human platelet-derived growth factor receptor 
alpha polypeptide (NCBI RefSeq: NM_006206.4). 
 
pEGFP-c1 (Clontech): An eukaryotic expression vector for fusing enhanced green 
fluorescent protein to the C-terminus of a partner protein. Here it was used as an indicator 
of transfection efficiency. 
 
2.1.8 Antibodies 
Antibody Source 
Primary antibodies and antiserum:  
  mouse anti-HCMV IE1 PerkinElmer, Waltham, US  
  mouse anti-HCMV gB (IP), (SM5-1) kindly provided by M. Mach (University 
Erlangen-Nürnberg, DE) 
  mouse anti-HCMV gB (WB), (2F12) Biozol, Echingen, DE 
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Antibody Source 
  mouse anti-HCMV gH (IP), (14-4b) kindly provided by W. Britt (University of Alabama, Birmingham, US) 
  mouse anti-HCMV gH (WB), (SA4) 
kindly provided by M. Mach (University 
Erlangen-Nürnberg, DE) 
  mouse anti-HCMV gO, (gO.02) 
kindly provided by Stipan Jonjic (University of 
Rijeka, Croatia) 
  mouse anti-MCMV ie1, (Croma 101) 
  mouse anti-PDGFRα (C-9) SANTA CRUZ 
  rabbit anti-HCMV pUL131A, (3058)  [94] 
Secondary antibodies:  
goat anti-mouse IgG (Fc Specific)-peroxidase A0168, Sigma-Aldrich, Steinheim, DE 
  sheep anti-mouse-peroxidase 515-035-062, Dianova, Hamburg, DE 
  goat anti-mouse light chain (κ)-peroxidase 115-035-174, Dianova, Hamburg, DE 
  goat anti-rabbit-peroxidase 111-035-003, Dianova, Hamburg, DE 
  Alexa Fluor 488-goat-anti mouse A-11001, Invitrogen, Karlsruhe, DE 
  mouse anti-human β Actin)-peroxidase AC-74, Sigma-Aldrich, Steinheim, DE 
  anti-mouse IgG (Fc specific)−biotin B9904, Sigma-Aldrich, Steinheim, DE 
  streptavidin-peroxidase polymer S2438, Sigma-Aldrich, Steinheim, DE 
 
2.1.9 Cells and media 
 
2.1.9.1 Prokaryotic cells 
E.coli Features Remarks 
DH10
B 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 endA1 
recA1 deoR Δ(ara, leu) 7697 araD139 galU galK nupG rpsL λ [177] 
Invitrogen, 
Karlsruhe, DE 
 
2.1.9.2 Eukaryotic cells 
Cells Description Remarks 
293 Human kidney epithelia cells  ATCC, CRL-11268™ 
ANA-1 Murine bone marrow-derived macrophage-like cells [178] 
ARPE-19 Human retinal pigmented epithelial cells ATCC® CRL2302™ 
HFF Human foreskin fibroblasts from PromoCell 
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Cells Description Remarks 
HUVEC Human umbilical vein endothelial cells From Lonza 
MEF Murine embryonic fibroblasts Own prepared from BALB/c mice 
MHEC-5T Murine heart endothelial cells [179] 
MRC-5 Human lung fibroblasts ATCC® CCL-171™ 
NIH3T3 Murine embryo fibroblasts ATCC® CRL-1658™ 
TCMK-1 Murine kidney epithelial cells ATCC® CCL-139™ 
TIME Human telomerase-immortalized microvascular endothelial cells [180] 
 
2.1.10 Viruses 
Cloning of herpesvirus genomes as bacterial artificial chromosomes (BACs), allows the 
maintenance and rapid engineering of viral genomes within E. coli. Virus can be 
reconstituted by transfection of the BAC plasmid in permissive eukaryotic cells. Human 
cytomegalovirus strain TB40/E was originally isolated from a bone marrow transplant 
recipient [34] and then cloned as a bacterial artificial chromosome (BAC) [181]. It is an 
endotheliotropic HCMV strain which is widely used around the world. All viruses used were 
derived from a wildtype BAC clone of TB40/E, TB40-BAC4 [181]. 
TB40-BAC4: A BAC clone containing the complete sequence of HCMV strain TB40/E. Virus 
reconstituted from TB40-BAC4 shows wildtype-like growth properties. 
TB40-UL131stop: A TB40-BAC4 mutant generated by introducing a G to A exchange at 
position 20 in ORF UL131, resulting in a stop mutant. 
TB40-ΔgO: A TB40-BAC4 mutant generated by deleting the first 533 nucleotides of ORF 
UL74 from TB40-BAC4. 
TB40-Luc: ORFs UL5 to UL9 were deleted from the TB40-BAC4 genome, and then a 
luciferase report gene inserted into TB40-BAC4△UL5-UL9 genome. TB40-Luc shows 
wildtype-like growth properties in cell culture. 
TB40-UL131stop-Luc: A TB40-Luc mutant generated by introducing a G to A exchange at 
position 20 in ORF UL131, resulting in a stop mutant. 
TB40-ΔgO-Luc: A TB40-Luc mutant generated by deleting the first 533 nucleotides of the 
ORF UL74. 
 
Mouse cytomegalovirus strain Smith was originally isolated from salivary glands of infected 
laboratory mice [182]. It was cloned as a bacterial artificial chromosome (BAC) named 
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pSM3fr [183, 184]. A frameshift mutation within the open reading frame (ORF) of MCK-2 
was repaired later and named pSM3fr-MCK-2fl [185]. MCMV BACs used here were all 
derived from pSM3fr-MCK-2fl [185]. 
 
 
2.1.11 Software  
Software Company 
Microsoft Office (Excel, Powerpoint, Word) Microsoft 
FACSDiva BD Biosciences 
GraphPad Prism 5 GraphPad Software 
Vector NTI Thermo Fisher Scientific 
Image J Developed by NIH for public 
Image Lab Bio-Rad 
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2.2 Methods 
 
2.2.1 Cultivation of bacteria 
DH10B were grown at 37°C either in suspension (LB-medium) or on agar-plates (LB-agar). 
The respective antibiotics were added for plasmid selection (see below). Cell density was 
determined by measuring the optical density of a bacterial suspension at 600 nm (OD600). 
OD600 of 1 corresponds to approximately 1×108 cells/ml. 
Medium Composition 
LB-medium 10 g Bacto™
 
Trypton, 5 g Bacto™
 
Yeast Extract, 5 g NaCl, 
in 1 L H2O 
LB-Agar 15 g Bacto™ Agar, in 1 L LB-medium 
 
Antibiotics 
ampicillin 50 μg/ml 
zeocin 30 μg/ml 
  
2.2.1.1 Glycerol stocks 
To maintain plasmid-carrying bacteria, glycerol stocks were prepared by adding 500 μl 50% 
glycerol to 500 μl dense bacterial culture. Stocks were stored at -80°C. 
 
2.2.1.2 Preparation of electrocompetent bacteria 
To prepare competent cells which are susceptible to introduction of foreign DNA by 
electroporation, 150 ml LB-medium was inoculated with 1.5 ml overnight DH10B culture 
and grown at 37°C to reach an OD600 of about 0.4. All following steps were conducted at 
low temperatures at 4°C. Briefly, bacteria were cooled on ice for 15 min and then pelleted 
by centrifugation at 5,500×g for 10 min and subsequently washed for 3 times with 100 ml 
10% glycerol. The bacterial pellet was finally resuspended in 1 ml 15% glycerol and snap 
frozen in liquid nitrogen as 70 μl aliquots and stored at –80°C. 
 
2.2.1.3 Transformation of bacteria 
Plasmid DNA was introduced into bacterial cells by electroporation. Briefly, 70 μl competent 
cells were thawed on ice for 10 min and mixed with 10 μl ligation product (100 - 200 ng) or 
1 - 10 ng plasmid DNA. The mixture was transferred to a pre-cooled electroporation cuvette 
(Biorad; 0.2 mm in diameter) and electroporated (4.5 ms, 2,5 kV, 200 Ohm and 25 mFD). 1 
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ml antibiotic free LB-medium was immediately added to the mixture before incubation at 
37°C for 1 h. Then, 200 μl were plated on LB agar plates and incubated at 37˚C over night. 
 
 
2.2.2 Molecular biology 
 
2.2.2.1 Polymerase chain reaction (PCR) 
To amplify DNA fragments, PCR was performed using Expand High Fidelity Polymerase 
(Roche). The reaction was done in a total volume of 100 μl. The PCR reaction mixture and 
program are shown below: 
 
PCR reaction mixture 
Component Volume Final concentration 
10×Expand High Fidelity buffer 10 μl 1× 
10 mM dNTPs 2 μl 200 μM 
Forward primer (25 μM) 1 μl 500 nM 
Reverse primer (25 μM) 1 μl 500 nM 
Template DNA 2 μl 10 ng 
Expand High Fidelity enzyme mix 1 μl 3.5 U/reaction 
ddH2O added up tp 100 μl  
 
 
PCR program 
Step Temperature Time Cycles 
Initial Denaturation 94°C 5 min 1× 
Denaturation 94°C 30 s 
30× Annealing 52°C 30 s 
Elongation 72°C 70 s 
Final Elongation 72°C 5 min 1× 
End 4°C hold  
 
The PCR products were purified using the QIAquick® Gel Extraction-Kit (Qiagen) according 
to the manufacturer’s instruction. 
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2.2.2.2 Preparation and purification of plasmid DNA 
Plasmids were extracted from 3 ml or 200 ml overnight bacterial cultures using the illustra 
plasmidPrep Mini Spin Kit (GE Healthcare) for minipreparation and the Nucleobond® 
PC100 Kit (Macherey-Nagel) for maxipreparation respectively. The isolated plasmid DNA 
was eluted in TE buffer (50 μl for minipreparation and 200 μl for maxipreparation) and 
analyzed by restriction enzyme digestion. 
TE buffer (pH 7.5) 
10 mM Tris/HCl 
1 mM EDTA 
 
2.2.2.3 Determination of DNA concentration 
The concentration of isolated plasmid DNA was assessed by measuring the absorbance at 
260 nm using NanoDrop 1000 (Thermo Fisher Scientific). An OD260 of 1 = 50 μg/ml double-
stranded DNA. 
 
2.2.2.4 Restriction enzyme digestion 
1 μg (analytic digestion) or 5 μg (preparative digestion) DNA were digested with 1 U or 5 U 
of restriction enzyme, respectively. Digestions were performed in the appropriate buffer for 
1 - 3 h at the temperature recommended by the manufacturer. 
 
2.2.2.5 Agarose gel electrophoresis 
To analyze DNA after digestion with restriction enzymes, DNA samples were mixed with 
10×DNA loading buffer and then separated by gel electrophoresis in 0.8 - 1.5% 
agarose/TAE gels containing 1 μg/ml ethidium bromide. Gels were run for 30 to 60 min at 
120 V. DNA was visualized by UV light using the Gel Doc™ EZ Gel Documentation 
System. 
50×TAE buffer (pH 7.3) 10×DNA loading buffer 
2 M Tris/HCl 50 mM Tris pH7.6 
250 mM Na-acetate 60% glycerol 
50 mM EDTA 2.5 mg/ml orange G 
 
2.2.2.6 Isolation of DNA fragments from agarose gels 
DNA fragments were cut from the gel and purified using the QIAquick Gel Extraction Kit 
(QIAGEN) according to the manufacturer’s instruction. Purified DNA was eluted in 30 μl TE. 
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2.2.2.7 Dephosphorylation of DNA fragments 
To prevent recircularization of linearized plasmids, the 5' phosphate group was removed 
using Antarctic Phosphatase (AP). 1 unit of AP per μg DNA was added to the DNA in a final 
volume of 20 μl. The mixture was incubated at 37°C for 30 min followed by inactivation of 
AP at 65°C for 10 min. Dephosphorylated DNA was purified with using QIAquick Gel 
Extraction Kit according to the manufacturer’s instruction. 
 
2.2.2.8 Ligation of DNA fragments 
DNA fragments were mixed with 100 ng linearized vector at a molecular ratio of 1 : 3 to 1 : 
8, 1 unit of T4 DNA ligase added and then incubated at 16°C overnight. 
 
2.2.2.9 DNA sequencing 
Plasmids were sent to Sequiserve (Vaterstetten, DE) for sequencing. The sequencing 
results were analyzed using Vector NTI Advance software.  
 
 
2.2.3 Analysis of proteins 
 
2.2.3.1 Purification of IgG Fc-fusion proteins 
Supernatants from cells transfected (2.2.4.3) with vectors expressing IgG Fc fusion proteins 
were concentrated to roughly 5 ml using filters with pore diameters of 10 or 50 kDa 
(Millipore). These concentrated supernatants were mixed with the same volume of Protein 
A IgG Binding buffer, pH 8.0 (Thermo Fisher Scientific) and 100 μl protein A sepharose 
beads (GE Healthcare) followed by an overnight incubation at 4℃ on a overhead shaker 
The next day, beads were pelleted by centrifugation in a precooled centrifuge and bound 
proteins were eluted using protein A IgG elution buffer, pH 2.8 (Thermo Fisher Scientific) 
and neutralized with Tris/HCl buffer (1M, pH8.0). Eluted proteins were frozen in aliquots 
and stored at ﹣80℃. Amounts of Fc proteins were determined by a capture ELISA (see 
2.2.3.2) 
 
2.2.3.2 Precipitation of proteins in supernatant with ethanol 
To precipitate proteins in the supernatants, 1 ml supernatant of each sample was collected 
and mixed with 25 μl 5 M NaCl and 1 ml ethanol, followed by a 15 min centrifuge at 4 ℃. 
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Supernatants were then removed and the pellets were resuspended with 50 μl 2×sample 
buffer. 
2×sample buffer 
10% SDS 6 ml 
0.5 M Tris pH6.8 2.5 ml 
1-Thioglycerol 1 ml 
Glycerol 1 ml 
Bromphenol Blue sprinkling 
 
2.2.3.3 Enzyme-linked immunosorbent assay (ELISA) 
A capture-ELISA was used to quantify the levels of mouse IgG Fc proteins. All dilutions and 
washes were done with ELISA buffer and all incubations were performed at room 
temperature. Specifically, Pierce™ NeutrAvidin™ coated plates (Thermo Fisher Scientific) 
were washed for 3 times before wells were coated with the capture antibody (anti-mouse 
IgG-Biotin, Sigma) at 1 μg/ml for 1 h. Samples were diluted and standards were prepared 
using mouse IgG (Sigma) at concentrations of 800, 400, 200, 100, 50, 25, 12.5 and 0 ng/ml. 
After washing the antibody-coated plates for 3 times, samples and standards were applied 
to the wells (100 μl/well) and incubated for 30 min. Subsequently, wells were washed for 3 
times and then incubated with detection antibody (1:10000; anti-mouse IgG peroxidase, 
Sigma) for 30min, followed by another 3 washes. For colorimetric quantification, 100 μl 
TMB substrate reagent (BD Biosciences) was added to each well and reactions were 
stopped with 100 μl 10% phosphoric acid. Absorbance at 450 nm was measured with an 
ELISA plate reader. Standard curves were generated by plotting the absorbance (y axis) 
against the protein concentration (x axis). Concentrations of samples were determined 
using the standard curves. 
ELISA buffer (pH7.2) 
Tris/HCl 25 mM 
NaCl 150 mM 
BSA 0.1% 
Tween-20 0.05% 
 
2.2.3.4 Biotinylation of cell surface proteins 
To label cell surface proteins, a biotin reagent which does not enter cells was used. Cell 
monolayers were biotinylated in 0.5 mg/ml EZ-Link Sulfo-NHS-LC-LC-Biotin (Thermo 
Scientific) in PBS for 30 min at RT and the reaction was stopped by washing the cells 3 
times with 100 mM glycine in PBS. 
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2.2.3.5 Cell lysates 
To prepare total cell lysates, cell monolayers were directly lysed with 2×sample buffer and 
ultrasonicated. To extract cytosolic proteins, cells were lysed with cold standard lysis buffer 
containing proteinase inhibitor cocktail (Roche) for 1 h at 4°C on a roller mixer. Cell nuclei 
were pelleted at 13,000 rpm for 10 minutes at 4°C and the supernatants were harvested 
and stored at -80°C. For lysis of virions, virus stocks were directly mixed with the standard 
lysis buffer and extracted as above. 
Standard lysis buffer (50 ml) 2×sample buffer 
1 M Tris pH8.0  0.8 ml 10% SDS 6 ml 
NaCl 0.4 g 0.5 M Tris pH6.8 2.5 ml 
Triton X-100 0.5 ml 1-Thioglycerol 1 ml 
H2O to 50 ml Glycerol 1 ml 
  Bromphenol Blue sprinkling 
 
2.2.3.6 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein mobility depends on its size and mass-to-charge ratio. To separate proteins with 
different sizes, SDS-PAGE was used. Due to incorporation of SDS into lysed proteins, 
separation of proteins solely depends on size. Specifically, cells, virus lysates, or purified 
proteins were mixed with 2×sample, and heated for 5 min at 95°C prior loading. Proteins 
were separated by polyacrylamide gel electrophoresis (PAGE) for about 55 min at 170 V in 
running buffer. A prestained protein marker (Thermo Fisher Scientific) was loaded in parallel 
to allow determination of molecular weights. After electrophoresis, separated proteins were 
further analyzed by Western blot analysis. 
 
       Preparation of gels 
Component Stacking gel         Separating gel 
 5% 10% 15% 
ddH20 2.81 ml 4 ml 2.33 ml 
Tris/HCl 1.25 ml (0.5 M, pH6.8) 2.5 ml (1.5 M, pH8.8) 2.5 ml (1.5 M, pH8.8) 
10% SDS 50 μl 100 μl 100 μl 
Acrylamid/Bis-
acrylamide 30% 840 μl 3.3 ml 5 ml 
10% APS 50 μl 100 μl 100 μl 
TEMED 3 μl 5 μl 5 μl 
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10×Running buffer (1 L) 
Tris-Base 30 g 
Glycin 144 g 
10% SDS 100 ml 
H2O to 1 L 
 
2.2.3.7 Coomassie blue staining 
To directly visualize proteins in SDS gels, gels were rinsed 3 times for 10 minutes with 
ultrapure H2O and then incubated with coomassie staining solution for 3 h. After rinsing  two 
times with ultrapure H2O, gels were treated with destaining solution for 10 – 60 minutes. 
Staining solution Destaining solution 
0.02% Coomassie Blue G-250 10% Ethanol 
5% Aluminiumsulfat-(14-18)-Hydrat 2% orthophosphoric acid 
10% Ethanol  
2% orthophosphoric acid  
 
2.2.3.8 Silver staining 
A mass spectrometry compatible silver staining kit (FireSilver Staining Kit, Proteome 
Factory) was used to stain protein bands in SDS-PAGE gels according to the 
manufacturer's instruction. Specifically, all steps were performed in a clean environment 
with clean devices and reagents to avoid contaminations from operators (e.g. keratin)	 or 
from reagents (e.g. trypsin) which would interfere with efficient data acquisition and analysis 
of target proteins. Excised gel slices were transferred to a clean tray and fixed with fix 
solution for 2 h. Gels were then washed with 20% ethanol for 10 min followed by a 
sensitization with sensitizer solution for 1 min. Gels were subsequently washed twice with 
ultra pure water for 1 min and then equilibrated with silver solution for 30 min. After another 
wash with ultra pure water for 30 s, gels were developed first with pre-developer solution for 
1 min and then with developer solution for 1-15 min. Thereafter, reaction was stopped with 
stop solution for 20 min. Gels were stored in ultra pure water. 
 
2.2.3.9 Western blot analysis 
To detect specific proteins, Western blot analysis was used. Proteins separated on SDS-
PAGEs were transferred to a Hybond-ECL nitrocellulose membrane (Amersham) using a 
Mini-PROTEAN Tetra System (Bio-Rad), at 100 V for 1 h at room temperature (RT). Before 
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transfer, membranes and gels were incubated in blotting buffer for 2 minutes. Afterwards, 
membranes were blocked in blocking buffer for 1 h, and then incubated with a primary 
antibody diluted in blocking buffer. Incubations with primary antibodies were performed 
overnight at 4°C on a roller mixer. Membranes were washed five times (5×5 min) with TBST 
and then incubated with corresponding peroxidase-conjugated secondary antibodies in 
blocking buffer for 2 h at RT. After another five washes with TBST, specific bands were 
detected by chemiluminescence using the Pierce™ ECL Plus Western Blotting Substrate 
(Thermo Fisher Scientific) according to the manufacturer’s instructions. Blots were exposed 
to Hyperfilm™ ECL™ detection film (GE Healthcare ) and the images were developed by 
using the developing machine FPM-100A. If necessary, initial antibodies could be stripped 
with Restore™ Western blot Stripping Buffer (Thermo Fisher Scientific) for 8 to 15 minutes 
at room temperature. The nitrocellulose membrane was then washed with TBST, reblocked 
with 5% milk in TBST and reprobed with other primary antibodies  
 
Buffers used for Western blot 
Blotting buffer TBST Blocking buffer 1 Blocking buffer 2 
25 mM Tris 150mM NaCl TBST PBS, pH 7.4 
192 mM glycine 10 mM Tris/HCl, pH 8.0 5% skimmed milk powder 0.05% TWEEN 20 
20% methanol 0.1% Tween 20  1% BSA 
 
2.2.3.10 Ponceau S staining for Western blots 
To visualize transfer of proteins, the membranes were soaked in Ponceau S solution 
(Sigma) for 1 min following Western blotting. The membrane was then rinsed with distilled 
water. 
 
2.2.3.11 Mass spectrometry 
Proteins in gel slices from silver stained gels were identified with high resolution 
nanoHPLC-ESI-MSMS chromatography (Protein Factory, Berlin, Germany) and blasted 
against human cellular protein databases. 
 
2.2.3.12 Co-immunoprecipitation (Co-IP) 
Cells or viruses were lysed in 1 ml standard lysis buffer containing proteinase inhibitor 
cocktail (PIC, Roche) for 1 h on a roller at 4 °C. Afterwards, lysates were centrifuged at 
20,000x g at 4 °C for 10 min. Supernatants were transferred to new Epps and precleared 
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with 25 μl of 50 %protein A sepharose beads (GE Healthcare) for 1 h on a roller at 4 °C. 
This is followed by a 2 min centrifugation at 13,000x g to remove proteins unspecifically 
bound to beads. Supernatants were co-incubated with antibodies or Fc fusion proteins at 
4°C overnight. Protein-antibody complexes were precipitated with 50 μl of 50% protein 
protein A sepharose beads. The precipitates were dissociated in protein sample buffer and 
subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), followed by either silver 
stain or Western blot. 
 
2.2.3.13 Crosslinking of proteins bound to cell surfaces 
Cells were seeded in 10 cm dishes one day before crosslink. Cell monolayers were washed 
for 5 times with PBS and then detached with 4 ml Versene (Thermo Fisher Scientific) per 
dish. Subsequently, cells were pelleted, washed once with PBS and incubated with Fc 
proteins on ice for 90 min. Thereafter, cells were washed once with PBS and resuspended 
with the crosslinker 2 mM 3,3′-dithiobis(sulfosuccinimidyl propionate) (DTSSP, Thermo 
Fisher Scientific) dissolved in PBS. After another 90 min incubation on ice, crosslink 
reaction was stopped by adding Glycine buffer to a final concentration of 10 mM. Then, 
cells were pelleted and subjected to further analysis. 
 
2.2.3.14 Indirect immunofluorescence 
To detect specific cellular proteins or protein-protein interactions on cell surfaces, indirect 
immunofluorescence which relys on the specific interaction between fluorescent dye-
labeled antibodies and their antigen, was applied. 
 
1) Staining of fixed adherent cells. Cells in the 96-well plates were fixed with 50 μl fix buffer 
per well for 10 min at RT and then washed with PBS for 3 times followed by an incubation 
with antibodies (diluted in staining buffer) directed against cellular proteins or viral proteins 
if virus-infected cells were used for 45 min at 37℃. After washing for 3 times, infected cells 
were visualized by staining using a Fluor 488-coupled anti-mouse antibody (1:1000 diluted 
in staining buffer). For counterstaining of cell nuclei, cells were incubated in PBS containing 
2 μg/ml Hoechst 333258 (Invitrogen) for 1 min followed by washing 3 times with PBS. 
Staining of cells was analysed by fluorescence microscopy. Total cell nuclei and infected 
cells were counted by using the software ImageJ (National Institutes of Health). 
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fix buffer  staining buffer     
acetone  50% (v/v) FCS 2% (v/v)    
methanol 50%	(v/v) PBS 98% (v/v)    
 
2) Cell surface staining for FACS analysis. Flow cytometry analysis was used to assess the 
binding of Fc fusion proteins to cell surfaces. Cells were seeded to 10 cm dishes one day 
day ahead of the flow cytometry experiment. Cells were washed for 3 times with PBS and 
then detached with 4 ml/dish Versene (Thermo Fisher Scientific). Thereafter, all steps were 
carried out using precooled devices and reagents and all dilutions of antibodies and 
washings were done with staining buffer. Cells were pelleted and resuspended with mouse 
IgG Fc proteins for 90 min on ice. After washing once, cells were incubated with anti-mouse 
Fluor 488-coupled antibody for 30 min on ice in the dark. After 3 more wash steps, cells 
were resupended in PBS and analysed using a BD FACS Canto II cytometer. Data were 
analyzed by using BD FACS Diva software (BD Biosciences). 
staining buffer  
FCS 5% (v/v) 
PBS 95% (v/v) 
 
3) Intracellular staining for FACS analysis. For intracellular staining of viral ie protein in 
CMV infected cells, cells were harvested and fixed with fix buffer for 10 min at RT. After 
washing once with wash buffer, cells were incubated with mouse anti-ie antibody (croma 
101) diluted in staining buffer at 4℃ for 30 min on a roller mixer. After another washing, 
cells were stained with anti-mouse Fluor 488-coupled antibody at 4℃ for 30 min on a roller 
mixer. Thereafter, cells were pelleted and resuspended with fix buffer. Samples were then 
subjected to flow cytometry analysis  
fix buffer  wash buffer staining buffer  
formaldehyde  1% (m/v) saponin 0.03% (v/v) saponin     0.3% (v/v) 50% (v/v) 
PBS  PBS 99.97% (v/v) PBS          99.7% (v/v) 50%	(v/v) 
    BSA          1% (m/v)  
 
2.2.4 Cultivation of mammalian cells 
Mammalian cells were cultivated at 37℃, 8% CO2, in a humidified cell culture incubator, 
and regularly sub-cultured. For sub-culturing, medium was removed. Adherent cells were 
rinsed once with PBS and detached with 1.0 ml (for 10 cm culture dish) or 3 ml (for 15 cm 
culture dish) 0.25% Trypsin-EDTA solution for 1 to 5 min at 37℃. Reaction was stopped by 
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adding the corresponding medium and then reseeded into new dishes containing fresh 
medium and incubated at 37°C. 
 
2.2.4.1 Cultivation of primary cells 
HFF (passage 7-23) and MEF (passage 1-3) were cultured in DMEM supplemented with 
10% FBS, 0.3 mg/ml L-glutamine (only for HFF) and 100 U/ml penicillin + 100 U/ml 
streptomycin. HFF were split 1:3 once a week and MEF were split 1:2 once a week. 
 
HUVEC, passage 1-6, were cultured in Lonza EGM™-2MV medium, and split 1:3 twice a 
week. 
 
2.2.4.2 Cultivation of cell lines 
293, MHEC-5T, NIH3T3 and TCMK-1 cells were cultured in DMEM supplemented with 10% 
FBS (5% for NIH3T3 and MHEC-5T) and 100 U/ml penicillin +100 U/ml streptomycin. 293 
were split 1:10 twice a week, NIH3T3 and TCMK-1 1:4 twice a week, and MHEC-5T 1:6 
once a week. 
 
ANA-1 and ARPE-19 cells were cultured in RPMI 1640 medium supplemented with 10% 
FBS and 100 U/ml penicillin + 100 U/ml streptomycin. ANA-1 were split 1:6 twice a week 
and ARPE-19 1:4 twice a week. 
 
TIME cells were cultured in EGM-2 MV SingleQuot Kit Suppl. & Growth Factors, split 1:3 
twice a week, and fed once in between. 
 
2.2.4.3 Freezing of cells 
Cells were harvested at 90% confluence and then pelleted at 300×g for 5 min at RT. Cell 
pellets were resuspended in freezing medium at a density of 1 × 106 cells/ml and 1 ml 
aliquots dispensed into cryo tubes (Nunc), which were then placed in an isopropanol 
isolated cryo-box and transferred to -80°C. Forty-eight hours later, cells were transferred to 
a nitrogen tank for long-term storage. For recovery of frozen cells, frozen cells were quickly 
thawed at 37 ºC in a water bath, then resuspended in 10 ml fresh cell-type specific medium 
and seeded into appropriate dishes. 
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Freezing medium 
70% cell-type specific medium 
20% FBS 
10% DMSO 
 
2.2.4.4 Transfection of cells 
Two methods of transfection were used in this study. 293 cells were seeded into 10 cm 
dishes or 6-well plates one day before the experiment to reach an 80% confluence at the 
time of transfection. Cells were either transfected with vector expressing Fc fusion protein 
using polyethylenimine (PEI) or with FuGENE HD (Promega). A plasmid expressing EGFP 
(pEGFP-C1, Clontech) was transfected in parallel to evaluate the transfection efficiency. 
For transfection, the following mixture was prepared for each dish in a 1.5 ml Epp. tube, 
and standing for 30 min at RT. The original medium was exchanged with Opti-MEM serum-
free medium (Gibco, Invitrogen) three hours after transfection.  
Transfection with PEI (for 10 cm dishes) Transfection with FuGENE HD (for 6-well plates) 
Opti-MEM 400 μl Opti-MEM 100 μl 
Plasmid 12 μg Plasmid 6 μg 
PEI 60 μl FuGENE HD 15 μl 
 
2.2.6 Virological methods 
 
2.2.6.1 Virus infection of cells 
Cells were seeded one day before infection to achieve 80% - 90% confluence. To infect 
cells, virus inocula were diluted in medium and applied to cells for 1.5 h at 37°C. To remove 
the inocula, cells were washed three times, supplied with fresh medium and incubated at 
37°C. In infection experiments using TB40-ΔgO virus, all virus infections were subjected to 
a centrifugation step (2.000 g at RT, 30 min), followed by incubation at 37°C for 60 min. 
 
2.2.6.2 In vitro amplification and purification of CMV particles 
To prepare virus inocula, three different methods were used.  
1) Supernatant virus. Supernatants of infected cells with complete cytopathic effects were 
centrifuged at 5.500 g for 15 min to remove cellular debris, aliquoted and frozen at -80°C. 
 
2) Virus stocks. For the preparation of virus stocks, eight to twelve 15 cm dishes of NIH3T3 
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(MCMV) or HFF (HCMV) were infected at a multiplicity of infection (MOI) of 0.1 to 1. 
Supernatants of infected cells showing a complete cytopathic effect were precleared at 
5.500 g for 15 min. All following steps were performed at 4℃ or on ice. Virus particles were 
pelleted at 26.000 g for 3 h for MCMV or at 21.000 rpm for 70 min for HCMV (Beckmann, 
SW32Ti). Virus pellets were resuspended in DMEM containing 5% FBS (1/200 - 1/500 of 
the starting volume) and stored in small aliquots at -80°C. 
 
3) For the preparation of sucrose-cushion-purified MCMV, virus pellets as described under 
2). Pellets were then resuspended and dounced in 3 ml VSB buffer. Then, ten ml VSB 
buffer containing 15% were overlaid with the virus suspension. Viruses were subsequently 
pelleted through the sucrose cushion by ultracentrifugation at 21.000 rpm for 70 min 
(Beckmann, SW32Ti). After washing once with VSB buffer, virus pellets were resuspended 
in 1.5 ml VSB buffer, aliquoted and stored at -80℃. 
VSB buffer (pH 7.8) 
Tris/HCl 0.05 M 
KCl 0.012 M 
EDTA (Na2 salt) 0.005 M 
 
2.2.6.3 Determination of viral titers of CMV preparations 
Virus titers were determined with a TCID50 assay performed on MEF (MCMV) or HFF 
(HCMV) in 96-well plates. Specifically, cells were seeded on 96-well plates in a volume of 
100/well one day before infection. Virus was 10-fold serially diluted in DMEM containing 5% 
FBS from 10-1 to 10-8. 100 μl/well diluted virus were added in quadruplicates onto 
corresponding cells, followed by incubation at 37°C for 3-4 days (MCMV) or 7-9 days 
(HCMV). To identify plaque positive wells, medium was removed and cells were stained 
with 1×crystal violet for 10 min at RT. After 3 times of washing with water, both plaque 
positive and plaque negative wells were counted under the microscope and virus titers were 
calculated according to the Reed and Muench method [186]. 
 
10×crystal violet (in PBS) 
formaldehyde 10 % 
crystal violet 1 % (w/v) 
EDTA (Na2 salt) 0.005 M 
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2.2.6.4 Luciferase assay 
A luciferase assay was used to evaluate infection capacities of HCMV expressing the firefly 
luciferase in different cell types. Briefly, HFF or 293 cells were grown in 96 well plates 
(20,000 cells/well) and infected in triplicates for 1.5 h at 37°C. Thereafter, inocula were 
replaced with 100 μl fresh medium supplemented with 300 μg/ml phosphono acetic acid 
(PAA) to block viral replication. 48 hours post infection, supernatants were removed and 
cells were directly lysed on the plate in 50 μl 1×lysis buffer (Luciferase Reporter Assay Kit I, 
PromoKine) for 10 min at RT on a shaker. Subsequently, 20 μl of the lysates were 
transferred to a light-proof 96-well plate,	 mixed with 40 μl/well firefly substrate (Luciferase 
Reporter Assay Kit I, PromoKine) and the luciferase activity was measured using the 
CLARIOstar microplate reader (BMG LABTECH GmbH). 
 
2.2.7 Statistical analysis 
All statistics and calculations were conducted with Prism 6.0 software (GraphPad, CA). The 
statistical significance between two groups was determined by unpaired student’s two-tailed 
t-test and Mann-Whitney Rank Sum test. All significance tests were denoted as: n.s. means 
p>0.05; * means 0.01 < p < 0.05; ** means 0.001 < p < 0.01; *** means p < 0.001. 
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3 Results 
 
3.1 The role of the HCMV envelope glycoprotein gO in infection 
Envelopes of all herpesviruses contain gH/gL glycoprotein complexes which promote virus 
entry. The glycoprotein O (gO) of HCMV binds to gH/gL to form a gH/gL/gO complex. gO, 
with a size of 464 amino acids (aa), is the protein product of the UL74 open reading frame 
(ORF). It contains an N-terminal signal sequence which is cleaved during processing. It is 
highly glycosylated and runs in an SDS-polyacrylamide gel at a size of about 125 kDa [91, 
92, 187]. 
 
HCMV mutants lacking gO (∆gO) release particles which are hardly infectious and show a 
focal, cell-associated spread pattern in cell culture [106, 107]. This focal spread is 
dependent on the alternative gH/gL/pUL(128,130,131a) complex [122]. To study ∆gO virus, 
large numbers of virus particles are needed to achieve infection levels which allow studies 
on the role of the gH/gL/gO complex. 
 
3.1.1 The role of gO in HCMV infection of different cell types 
All HCMV mutants used here are derived from TB40-BAC4, a bacterial artificial 
chromosome (BAC) clone of the HCMV strain TB40/E [181]. To compare the tropism of 
TB40-BAC4 (wildtype) with TB40-BAC4-∆gO virus for different cell types, BACs expressing 
firefly luciferase (TB40-Luc and TB40-∆gO-Luc) [122] were used to quantitatively analyze 
infection of cells. Infection of human foreskin fibroblasts (HFF), human lung fibroblasts 
(MRC-5), embryonic kidney epithelial cells (293), retinal pigmented epithelial cells (ARPE-
19) and human umbilical vein endothelial cells (HUVEC) was compared. The TB40-Luc and 
TB40-∆gO-Luc preparations used for infection of different cell types were adapted to give a 
comparable infection on HFF. The upper panel in Figure 8 shows the luciferase signal from 
infected cells. The lower panel shows relative infection capacities. Here, the signals were 
normalized to infection of HFF which was arbitrarily set to 100%. TB40-Luc showed a 
higher capacity to infect fibroblasts when compared to infection of epithelial cells and 
endothelial cells (EC). In contrast, TB40-BAC4-∆gO-Luc exhibited a relatively higher 
infection capacity for epithelial cells and EC when compared to infection of fibroblasts with 
TB40-Luc. Thus, the loss of gO and with it, the capability to form a gH/gL/gO complex is 
associated with a shift of relative infection capacities for certain cell types, which suggests 
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that infection of fibroblasts but not infection epithelial cells and EC is predominantly driven 
by the gH/gL/gO complex. If gH/gL/gO is missing, infection is driven by the 
gH/gL/pUL(128,130,131a) complex. This also implies that fibroblasts have more receptors 
for the gH/gL/gO complex than for gH/gL/pUL(128,130,131a) complex. 
 
Figure 8: Comparison of the infection capacities of wildtype TB40-Luc and TB40-ΔgO-Luc for different 
cell types in culture. 
Fibroblasts (HFF and MRC-5), epithelial cells (293 and ARPE-19) and EC (HUVEC) were infected with TB40-
Luc or TB40-ΔgO-Luc. Infection capacities were determined 24h p.i. by a luciferase assay. The upper panel 
shows the luciferase signal measured in infected cells. The lower panel shows infection capacities relative to 
the infection capacity for HFF which is set to 100%. Shown are means +/- SD of 3 independent experiments 
done in triplicates. Unpaired student's t-test was performed for statistical analysis. (* means 0.01 < p < 0.05; ** 
means 0.001 < p < 0.01; *** means p < 0.001) 
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3.1.2 Cloning of a gO-Fc fusion protein to study the role of HCMV gO in infection of 
host cells 
 
3.1.2.1 Cloning and expression of a gO-Fc fusion protein 
It has been suggested that HCMV gO mediates HCMV entry into fibroblasts via interaction 
with a fibroblast-specific cell surface protein [68]. To create a tool to study the interaction of 
gO and potential cellular receptors, a gO-IgG Fc fusion protein was cloned. Secreted IgG 
Fc fusion proteins can be purified from supernatants of transfected cells using protein A 
sepharose beads. In addition, they are good tools for coimmunoprecipitation of binding 
partners. There have been several studies using IgG Fc-fused viral glycoproteins to identify 
the corresponding cellular receptors. For example, HLA class II was identified as a binding 
partner for gp42 which is a component of the Epstein-Barr virus gH/gL/gp42 glycoprotein 
complex [188]. Another group successfully precipitated EphrinB2 as an entry receptor for 
Nipah virus [189].  
 
The TB40-BAC4 gO ORF without the N-terminal signal sequence (aa1 - aa 20) [190] was 
cloned into the eukaryotic expression vector pFUSE-mIgG2b-Fc2 (InvivoGen) which 
expresses the mouse IgG2b Fc. It also expresses an IL-2 secretion signal (IL-2ss) for 
release of the recombinant protein (Figure 6a, adapted from InvivoGen). The DNA 
sequence of gO (bp 86 to bp 1392), was amplified from a pSG5 vector expressing the 
complete gO sequence (see Materials and Methods) and inserted into the vector pFUSE-
mIgG2b-Fc2 between the N-terminal secretion signal IL-2ss and the mouse IgG2b Fc using 
an Nco Ⅰ site and a Bgl Ⅱ site in the multiple cloning site (Figure 9a and 9b). This 
expressing vector was called pgO-Fc and was subsequently used for the production of gO-
Fc protein in transfected cells. 
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Figure 9: Schematic presentation of pFUSE-gO-mIgG2B-Fc. 
The gO ORF lacking the signal peptide was amplified and cloned into the plasmid pFUSE-mIgG2B-Fc2. 
Shown are a) the map of the vector and the corresponding insertion site (adapted from InvivoGen) and b) a 
schematic presentation of the structure of the fused gO-Fc. 
 
For expression of gO-Fc, 293 cells were transfected with pFUSE-gO-mIgG2B-Fc or the 
empty vector as a control. Supernatants were collected 24h after transfection and proteins 
were precipitated with ethanol. Expression of gO-Fc was then tested by Western blot 
analysis (Figure 10). The molecular weight of the mouse IgG Fc protein is about 35kDa. 
The recombinant gO-Fc showed a molecular weight of around 150 kDa. 
 
Figure 10: Secretion of Fc and gO-Fc into supernatants of transfected 293 cells. 
293 cells were transfected with pFUSE-mIgG2B-Fc (1) or pFUSE-gO-mIgG2B-Fc (2). The cell culture 
supernatants of the transfected cells were harvested after 24h, precipitated with ethanol, and analyzed by 
Western blot. Secreted Fc and gO-Fc were detected using a peroxidase-conjugated anti-mouse Fc antibody. 
The positions of the molecular weights of the marker are indicated on the left. 
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A capture ELISA detecting mouse IgG Fc (see Methods) was used to evaluate the amount 
of IgG Fc and gO-Fc. Measurements revealed that gO-Fc was produced in much lower 
amounts than IgG Fc. This may be due to the large size and the abundant glycosylation of 
the gO-Fc fusion protein. To express and purify large amounts of gO-Fc, different 
experimental conditions were tested to achieve an optimal yield. Briefly, 293 cells were 
transfected with pFUSE-gO-mIgG2B-Fc. Supernatants were collected and concentrated 
using filters with a cutoff of 50 kDa, followed by purification with protein A sepharose beads. 
For transfection, three commercially available reagents (FuGENE HD (Roche), PEI (Sigma) 
and SuperFect (Qiagen)) and different ratios of DNA versus transfection reagents for vector 
transfection were compared. In addition, operability and productivity of 6-well plates and   
10 cm dishes were also compared. For the time point of harvest, 96 h after transfection was 
superior to the time points 24h and 48h after transfection. Additionally, binding of gO-Fc to 
protein A sepharose was strongly reduced when the supernatant was concentrated too 
much. A comparison of protein A sepharose beads in suspension to commercial protein A 
columns (NAbTM Protein A plus Spin Column, Cat. No. 89956, Thermo Scientific) gave a 
better yield for the beads in suspension. To achieve a high elution efficiency, different 
elution buffers with different pH were compared. In the end, the optimized protocol was to 
transfect ten 10 cm dishes, harvest at 96 hours after transfection, concentrate to about 5ml, 
purify with protein A sepharose beads and elute with a pH 2.8 buffer. This protocol 
produced gO-Fc protein yields of around 3 - 16 μg/ml (Figure 11). 
 
Figure 11: Production and purification of gO-Fc. 
10 x 10cm dishes of 293 cells were transfected with pFUSE-gO-mIgG2B-Fc. The cell culture supernatants of 
these cells were harvested after 96h, concentrated to 5ml (before binding), bound to protein A sepharose 
beads (supernatant after binding was denoted “after binding”), washed 3 times with binding buffer (collected 
washing buffer was named “wash”) and eluted 3 times with elution buffer (pH 2.8) (Fraction 1, Fraction 2 and 
Fraction 3). The eluates were immediately neutralized with 1M Tris-HCl (pH 8.5) and analyzed by Western 
blot (a) and ELISA (b). C: concentration. 
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3.1.2.2 Binding properties of gO-Fc 
To find out whether the gO-Fc fusion protein binds to the surface of HCMV host cells, gO-
Fc was coincubated with fibroblasts (HFF) and EC (HUVEC) and the cells analyzed by flow 
cytometry. gO-Fc only bound to HFF, but not to HUVEC, while the control Fc protein bound 
to neither cell type (Figure 12). This binding pattern of gO-Fc correlates with the infection 
capacity of HCMV mutants expressing only the gH/gL/gO complex which can infect 
fibroblasts, but fail to infect EC [94]. 
 
 
Figure 12：gO specifically binds to fibroblasts. 
IgG Fc protein (green line) or gO-Fc protein (orange line) or buffer (brown line and filled histogram) were 
coincubated with HFF (left panel) or Huvec (right panel). Cell-surface binding was detected using an Alexa 
Fluor® 488 conjugated anti-mouse IgG secondary antibody. 
 
To clarify whether gO-Fc binding to fibroblasts is dose dependent, binding of serially diluted 
gO-Fc protein was analyzed. A dose-dependent binding pattern could be observed (Figure 
13). 
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Figure 13: Binding of gO-Fc to fibroblasts is dose-dependent. 
Two-fold serial dilutions of one prep of gO-Fc protein were coincubated with HFF. Cell-surface binding was 
detected by flow cytometry using an Alexa Fluor® 488 conjugated anti-mouse IgG secondary antibody.  
 
3.1.2.3 Blocking of HCMV infection using gO-Fc 
Since gO-Fc bound to the surface of HFF, it might be used to block HCMV infection. As 
depicted in Figure 14, soluble gO-Fc might bind a potential entry receptor on HFF and thus 
interfere with gO-dependent infection of fibroblasts. 
 
 
Figure 14: Scheme for an inhibition assay using purified gO-Fc fusion protein. 
Pre-incubation of HFF with gO-Fc and binding to cell surface receptors. Infection of HFF mediated by the 
gH/gL/gO is blocked. 
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To test this, HFF were preincubated with gO-Fc or as a control IgG Fc alone. HCMV 
mutants expressing only the gH/gL/gO complex (TB40-UL131stop-Luc) or expressing only 
the gH/gL/pUL(128,130,131a) complex (TB40-∆gO-Luc) were used to infect HFF in the 
presence of gO-Fc or IgG Fc, respectively, followed by removal of the virus inoculum. 
Infected cells were quantified by measuring luciferase activity in lysates 24h after infection. 
Preincubation with gO-Fc neither inhibited TB40-Luc nor TB40-∆gO-Luc (Figure 15). This 
might have several reasons: i) Binding of gO-Fc to HFF turned out to be temperature 
sensitive: the binding at 4 ℃ was strong, whereas there was no binding at room 
temperature. Infection has to proceed at 37 ℃, which probably results in detachment of gO-
Fc. ii) gO-Fc binding might be less strong than binding of gH/gL/gO in virions and thus not 
capable to compete with complexes in virions. iii) The amount of gO-Fc was not sufficient to 
block all receptors. 
 
 
Figure 15: gO-Fc protein does not inhibit HCMV infection. 
HFF were preincubated with gO-Fc or as a control IgG Fc on ice for 1 hour, then infected by TB40-
UL131stop-Luc or TB40-∆gO-Luc in the presence of gO-Fc or IgG Fc for 1.5 hours, followed by removal of the 
virus inocula and 3 washes. Thereafter, cells were fed with medium containg 300 μg/ml PAA. Infected cells 
were quantified by measuring luciferase activity in lysates 24 h p.i.. Shown are the means ± SD of one 
experiment assayed in triplicates. 
 
3.1.3 Identification of PDGFRα as a receptor for HCMV gH/gL/gO 
HCMV enters host cells through a complex process involving the interaction of cellular 
receptors and viral glycoproteins [50]. Several cell surface proteins have been reported to 
interact with HCMV envelope glycoproteins and facilitate the HCMV entry process, 
however, none of them is currently confirmed to be a functional entry receptor [50].  
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3.1.3.1 Identification of PDGFRα as a binding partner for HCMV gH/gL/gO 
Previous studies have demonstrated that the gH/gL/gO complex mediates binding of HCMV 
to fibroblasts [68]. Consistent with that, a gO-Fc fusion protein specifically bound to HFF. In 
a step it was determine whether gO-Fc could precipitate a cellular receptor from extracts of 
HFF. Co-immunoprecipitation (Co-IP) is a widely used method to identify interaction 
partners of viral proteins. For a start, it was tested whether gO-Fc can precipitate cell 
surface proteins from extracts of HFF. HFF were biotinylated with Sulfo-NHS-Biotin and 
then incubated with equal amounts of either gO-Fc or the control IgG Fc protein, followed 
by lysis of the cells and precipitation with protein A sepharose beads. Biotinylated proteins 
were detected by Western blot using peroxidase-conjugated streptavidin. This experiment 
was repeated several times and a reproducible, but weak biotinylated protein band with a 
molecular weight of about 180 kDa was detected in the gO-Fc precipitates but not in Fc 
precipitates. Due to a high background, it was not possible to document this by scanning 
the Western blot films. Additionally, a silver staining of an SDS-PAGE gel of the same 
extracts was done but no corresponding band could be detected. 
 
Assuming that binding of virion gH/gL/gO complex to its cellular receptor might be stronger 
than binding of recombinant gO-Fc, a TB40-BAC4 mutant expressing gH/gL/gO but not the 
gH/gL/pUL128-131 (TB40-UL131stop [122]) was used for binding to cells and subsequent 
co-precipitation of host cell proteins. For a preliminary test, TB40-UL131stop [122] virions 
were lysed to evaluate whether an anti-gH (14-4b) antibody could precipitate the gH/gL/gO 
complex and associated proteins. As shown in Figure 16, gO could be co-precipitated with 
gH, indicating that the anti-gH antibody precipitates the gH/gL/gO complex and can thus 
could be used to precipitate cellular proteins which interact with gH/gL/gO. 
 
Figure 16: Co-immunoprecipitation of gO and gH from TB40-UL131stop virions. 
TB40-UL131stop virions were lysed and gH was precipitated using an anti-gH antibody (14-4b). gO and gH 
were detected by Western blot analysis using mouse anti-gO antibody (gO.02) and mouse anti-gH antibody 
(SA4) respectively. A peroxidase-conjugated goat anti-mouse IgG served as detecting antibody. gO and gH 
were detected in virion lysates and in the precipitates. Mouse IgG served as a control antibody for Co-IP. 
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Again, a biotinylation assay was performed to detect cell surface binding partners of the 
gH/gL/gO complex using a similar strategy as for gO-Fc. gH/gL/gO-interacting proteins 
were precipitated using the above tested mouse anti-gH antibody. HFF cells were labeled 
with Sulfo-NHS-Biotin, then either cells coincubated with TB40-UL131stop virions on ice 
followed by lysis of cells and virions bound to cells or virion lysates were mixed with lysates 
of biotinylated cells. gH was precipitated from these lysates using the mouse anti-gH 
antibody used above (Figure 17a). A predominant biotinylated band with a molecular weight 
of about 180kDa could be detected using both approaches but not in lysates of HFF cells 
only (Figure 17a). The band could also be detected in silver stained gels (Figure 17b). It ran 
at the same position as the 180 kDa band detected when using gO-Fc for precipitation of 
cell surface proteins. To identify this protein, the immunoprecipitation approaches were 
repeated without biotinylation of the HFF cell surface. The 180 kDa band in the silver-
stained gel and the corresponding area in the HFF control lane were excised and sent out 
for nanoHPLC-ESI-MS/MS analysis (Proteome Factory, Berlin). A peptide 
(KLVYTLTVPEATVKD) derived from platelet-derived growth factor receptor-alpha 
(PDGFRα) was identified (Figure 17c). 
 
Figure 17: Identification of PDGRFα as a potential cellular receptor for HCMV. 
TB40-UL131stop virions were mixed with HFF either before (surface) or after lysis (extract), incubated with 
the anti-gH antibody (14-4b) and then precipitated with protein A sepharose beads. a. Cell surface proteins 
were prelabeled with Sulfo-NHS-Biotin before addition of virions or virion extracts. Anti-gH precipitated 
proteins were analyzed by Western blot using peroxidase-conjugated streptavidin. b. Precipitates were 
separated by SDS-PAGE and visualized by silver staining using the FireSilver protein gel staining kit. c. 
Bands excised from silver-stained gels (boxed areas) were sent out for nanoHPLC-ESI-MS/MS analysis and a 
peptide from human PDGFRα was identified. 
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3.1.3.2 Confirmation of PDGFRα as a binding partner for gH/gL/gO 
To confirm the PDGFRα co-precipitation, the precipitated proteins were additionally 
subjected to Western blot analysis: precipitation of gH and co-precipitation of gO, PDGFRα 
and additionally, gB was detected (Figure 18). 
 
 
Figure 18: Coprecipitation of gH, gO, gB and PDGFRα. 
Precipitates from figure 13 were additionally analyzed by Western blot using anti-gH antibody (SA4), anti-gO 
antibody (gO.02), anti-gB antibody (2F12) and anti-PDGFRα antibody (C-9) as first antibodies, and a 
peroxidase-conjugated goat anti-mouse IgG as detecting antibody. Arrows indicate the corresponding 
proteins. 
 
3.1.3.3 Characterization of the interactions of gH/gL/gO, gB and PDGFRα 
A co-precipitation of gB and PDGFRα has been shown before [72]. In addition, it has been 
shown that gB directly interacts with gH/gL [191]. In line with the previous finding, gB was 
also detected in our Co-IP samples with the anti-gH antibody. Therefore, it had to be 
clarified whether the observed interaction of gH/gL/gO, gB and PDGFRα, reflects an 
interaction of gH/gL/gO with PDGFRα through gB, whether gH/gL/gO binds both PDGFRα 
and gB, or whether both, gB and gH/gL/gO independently can interact with PDGFRα. 
 
To confirm the co-precipitations, it was tested whether a recombinant PDGFRα-Fc protein 
could also co-precipitate gH, gO and gB. As shown in Figure 19, PDGFRα-Fc 
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coprecipitated gO, gH and also gB, whereas PDGFRβ-Fc precipitated none of these 
proteins. Thus, the interactions are highly specific and promoted by PDGFRα. 
 
Figure 19: Co-immunoprecipitation of gO, gH, and gB from TB40-UL131stop virions with PDGFR-Fc 
proteins. 
TB40-UL131stop virion lysates were precleared with protein A sepharose beads, co-incubated with either 
PDGFRα-Fc or PDGFRβ-Fc. Proteins bound to Fc-fusion proteins were precipitated with protein A beads. 
Coprecipitated proteins were detected by Western blot using corresponding antibodies. Fc-fused proteins 
were visualized using a peroxidase-conjugated goat anti-human antibody. 
 
It has been described that gH and gB can interact during HCMV entry [97] or in transfected 
cells [67, 192]. Co-precipitation of gB and gH either using an anti-gH antibody (Figure 18) or 
PDGFRα-Fc protein (Figure 19) could be confirmed. To test whether there is an interaction 
between gB and gH in the absence of PDGFRα, co-immunoprecipitation experiments were 
performed using extracts of cell-free virions. As shown in Figure 20, anti-gH antibody 
precipitated gH, gO and also gB from purified virions. Anti-gB antibody could only 
precipitate gB, but not gH or gO. A likely explanation might be that the antibody recognizes 
an epitope which is also required for the interaction between gB and gH and blocked when 
complexes are formed. Consequently, only gB which is not in complexes can be 
precipitated by this antibody. Collectively, these data support the existence of a direct 
interaction between gB and gH in virions. This interaction very likely is independent of 
PDGFRα. 
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Figure 20: Immunoprecipitation of gH and gB from TB40-UL131stop virions. 
TB40-UL131stop virions lysates were precleared with protein A sepharose beads, incubated with either anti-
gH antibody (14-4B) or anti-gB antibody (SM5-1), which were then precipitated with protein A sepharose 
beads. Virion lysates and immunoprecipitates were detected by Western blot using corresponding first 
antibodies and a peroxidase-conjugated goat anti-mouse IgG (Kappa light chain) for gB and a peroxidase-
conjugated goat anti-mouse IgG for gH and gO as second antibodies.  
 
The experiments were replaced using wild type TB40 virus to test reproducibility in a virus 
expressing both the gH/gL/gO and gH/gL/pUL(128,130,131a) complexes. Figure 21 shows 
that PDGFRα, but not PDGFRβ precipitated gO and gB also from TB40-BAC4 virion 
lysates. Anti-gH antibody co-precipitated gB, gH and gO from mixed lysates of virions and 
cells. And again, anti-gB antibody only precipitated gB. 
 
Figure 21: Co-immunoprecipitation of gH, gO, gB and PDGFRα from lysates of TB40-BAC4 virions or 
TB40-BAC4 virions mixed with fibroblasts. 
TB40 virions lysates or mixtures of TB40 virions lysates and HFF lysates were incubated with PDGFR-Fc 
proteins or anti-gH antibody (14-4b) or anti-gB antibody (SM5-1), and then precipitated with protein A 
sepharose beads. Immunoprecipitates were detected by Western blot analysis using the corresponding first 
antibodies and a peroxidase-conjugated goat anti-mouse IgG (Kappa light chain) for gB and a peroxidase-
conjugated goat anti-mouse IgG for gH, gO and gB as second antibodies. Fc-fused proteins were visualized 
using a peroxidase-conjugated goat anti-human antibody. 
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3.1.3.4 PDGFRα and HCMV gO interact directly 
To find out whether gO can directly interact with PDGFRα, purified gO-Fc protein was co-
incubated with HFF on ice, and then crosslinked by adding water-dissolved DTSSP 
(membrane-impermeable protein crosslinker) into the mixture. After the crosslink, cells were 
lysed and proteins precipitated with protein A sepharose beads. As shown in Figure 22, gO-
Fc precipitated PDGFRα from HFF after crosslink whereas an interaction with PDGFRα in 
the absence of DTSSP was hardly detectable. This strongly suggests a direct interaction 
between gO and PDGFRα on the cell surface. 
 
Figure 22: Crosslink of gO-Fc and PDGFRα on the surface of HFF. 
HFF were detached with versene and incubated with or without gO-Fc on ice for 90 min. Samples were 
crosslinked or not with 2 mM DTSSP on ice for 90 min. Cells were lysed and Fc proteins precipitated using 
protein A sepharose beads. Precipitates were detected by Western blot analysis using the corresponding first 
antibodies and a peroxidase-conjugated goat anti-mouse IgG as the second antibody. 
 
 
3.2 The role of PDGFRα in HCMV infection 
PDGFRα has been reported to enhance HCMV infection [72]. Additionally, HCMV infection 
has been shown to result in phosphorylation of PDGFRα, yet inhibition studies with anti-
PDGFRα antibody, PDGFRα ligand or inhibitors of phosphorylation were inconclusive [72, 
74]. Thus, to date, it is still not clear whether PDGFRα serves as an entry receptor or as a 
coreceptor promoting entry by providing a costimmulation signal for HCMV host cells. 
 
3.2.1 Inhibition of infection with soluble PDGFRα protein 
HCMV infection of fibroblasts has been shown to be mediated by the gH/gL/gO complex 
[68]. If the entry process depends on an interaction of PDGFRα and gH/gL/gO, 
preincubation of virus with soluble PDGFRα protein might be able to inhibit infection. To 
evaluate that, TB40-Luc virions were preincubated with recombinant PDGFRα-Fc protein 
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(524 aa long N-terminus of human PDGFRα fused to human IgG1 Fc, R&D Systems) and 
then subjected to infection of HFF. Twenty-four hours post infection (p.i.), virus entry was 
quantified by measuring the luciferase activities of TB40-Luc. As shown in Figure 23, 
PDGFRα-Fc blocked TB40-Luc infection in a dose-dependent manner. Blocking could be 
saturated. PDGFRβ-Fc, which was used as a control, had no effect, indicating that HCMV 
entry into HFF specifically relies on a gH/gL/gO - PDGFRα interaction. 
 
 
Figure 23: PDGFRα-Fc blocks HCMV infection of HFF. 
HFF cells were plated in 96-well plates one day before infection. TB40-Luc virus was preincubated with the 
indicated amounts of soluble PDGFRα-Fc protein or as a control PDGFRβ-Fc for one hour at 4°C. Cells were 
infected with the virus-PDGFR-Fc mixtures using centrifugal enhancement (2000rpm, 30min; RT) followed by 
an incubation at 37℃ for 1h. Then cell layers were washed 3 times with PBS and incubated with medium 
containing PAA. Luciferase activity was measured 24h post infection (p.i.). Shown are means ± SD of one 
experiment performed in triplicates. 
 
To confirm that neutralization of HCMV by PDGFRα is gO-dependent, TB40-ΔgO-Luc virus 
(Figure 24b), which lacks gO and expresses only the gH/gL/pUL(128,130,131a) complex, 
was tested in parallel with TB40-Luc virus (Figure 24a) following the same strategy as 
above. Amounts of TB40-ΔgO-Luc virus and TB40-Luc virus were adapted to give a similar 
initial infection capacity on HFF. Notably, PDGFRα-Fc specifically blocked TB40-Luc 
infection but not TB40-ΔgO-Luc infection of HFF, suggesting that PDGFRα functions as a 
gH/gL/gO-specific receptor. 
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Figure 24: PDGFRα-Fc neutralizes TB40-Luc but not TB40-ΔgO-Luc infection of HFF. 
HFF cells were plated in a 96-well plate one day before infection. TB40-Luc (a) and TB40-ΔgO-Luc (b) virus 
were preincubated with the indicated amounts of soluble PDGFRα-Fc protein or as a control PDGFRβ-Fc for 
one hour at 4°C. Cells were infected with the virus-PDGFR-Fc mixtures using centrifugal enhancement 
(2000rpm, 30min; RT) followed by an incubation at 37℃ for 1h. Then cell layers were washed 3 times with 
PBS and incubated with medium containing PAA. Luciferase activity was measured 24h p.i.. Shown are 
means ± S.E. of 3 independent experiments assayed in triplicates. Unpaired student's t-test was performed 
for statistical analysis. (** denotes 0.01<p<0.01) 
 
The inability of PDGFRα-Fc protein to block infection of HFF with TB40-ΔgO confirms 
earlier findings [118] that entry via the pentameric complex relies on an alternative receptor. 
In line with that, infection with wildtype virus TB40-Luc which expresses both gH/gL/gO and 
gH/gL/pUL(128,130,131a) could not be completely inhibited (Figure 23), indicating a 
residual infection due to the pentameric complex. To verify this, TB40-UL131stop-Luc [122], 
a virus mutant lacking the pentameric complex was co-incubated with PDGFRα-Fc in 
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parallel with wildtype TB40-Luc. As shown in Figure 25, TB40-UL131stop-Luc infection, but 
not TB40-Luc could be completely inhibited, supporting that the residual infection is 
gH/gL/pUL(128-UL131a)-dependent entry, which is independent of PDGFRα. 
 
 
Figure 25: PDGFRα-Fc completely blocks TB40-UL131stop-Luc infection of HFF, but not TB40-Luc 
infection. 
HFF cells were plated in a 96-well plate one day before. TB40-Luc and TB40-UL131stop-Luc viruses were 
preincubated with the indicated amounts of soluble PDGFRα-Fc protein or as a control PDGFRβ-Fc for one 
hour at 4°C. Cells were infected with the virus-PDGFR-Fc mixtures using centrifugal enhancement (2000rpm, 
30min; RT) followed by an incubation at 37℃ for 1h. Then cell layers were washed 3 times with PBS and 
incubated with medium containing PAA. Luciferase activity was measured 24h p.i.. Shown are the means ± 
SD of one experiment performed in triplicates. 
 
3.2.2 gH/gL/gO determines infection of fibroblast cultures with free virus, but not cell-
associated spread 
HCMV spread in fibroblast cultures is determined by the gH/gL/gO complex and is 
predominantly driven by supernatant virus [122]. Deletion of HCMV gO results in release of 
hardly infectious virus particles and shifts the spread pattern from supernatant-driven to 
cell-associated spread [107].  
 
Infection of fibroblasts with free virus can be effectively inhibited with soluble PDGFRα 
(Figure 23 - 25). To study whether also cell-associated spread in cell culture is PDGFRα-
dependent, co-culture experiments were performed. TB40-BAC4 infected HFF were either 
mixed with uninfected HFF or HUVEC, and spread of infection followed in the presence or 
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absence of PDGFRα-Fc or as a control PDGFRβ-Fc or anti-pUL131a antibody, which 
specifically blocks gH/gL/pUL(128, 130, 131a)-dependent spread [94]. Spread of infection 
was monitored by staining for the HCMV immediate-early protein (IE1). For HCMV spread 
in HFF culture, only PDGFRα-Fc specifically reduced the number of infected cells per focus 
(Figure 26a and Figure 26b) to a level reminiscent to the effect of methylcellulose overlays, 
a treatment which restricts cell-free virus spread. This suggests that the reduced infection in 
fibroblast cultures is likely due to a PDGFRα-dependent neutralization of cell-free virus. The 
observation that the anti-pUL131a antibody had no effect on focus size in HFF, suggests 
that gH/gL/gO can also promote cell-associated spread independent of PDGFRα. Spread in 
HUVEC cultures was abolished by anti-pUL131a  antibody but not by PDGFRα (Figure 26a 
and 26c), supporting that HCMV spread in EC cultures is determined by gH/gL/pUL(128, 
130, 131a) and independent of PDGFRα. 
 
To conclude, gH/gL/gO likely promotes entry of cell-free virus through a PDGFRα-
dependent pathway and cell-associated virus spread through a PDGFRα-independent 
pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Results   
     63 
 
 
 
Figure 26: PDGFRα-Fc does not inhibit cell-associated spread of HCMV in fibroblast cultures. 
HFF were infected with TB40-Luc at an MOI of 10. 150 infected cells/well were then mixed with 1.5×104 
HFF/well or 2×104 HUVEC/well and seeded in 96-well plates. Supernatants were removed after 12 h and 
fresh medium containing anti-pUL131a serum or PDGFR-Fc proteins was added. These media were 
exchanged every second day. Cells were fixed after 5 days and infected cells were visualized by antibodies 
directed against HCMV IE1 and a goat anti-mouse Alexa Fluor® 488 antibody. a) representative microscopic 
fields. b) and c) IE1 positive cells of 10 randomly chosen foci were counted for each group. The error bars in b 
and c represent means ± SD. Mann-Whitney Rank Sum test was performed for statistical analysis (*** 
denotes p<0.001) 
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3.2.3 The infection capacity of HCMV for its host cells correlates with the abundance 
of PDGFRα 
Infection of cells with HCMV expressing only gH/gL/gO complex is highly restricted [114]. 
Mainly fibroblasts are susceptible to HCMV infection [68]. To find out whether this 
correlates with PDGFRα levels, PDGFRα protein levels of several HCMV-permissive cell 
types were assessed by Western blot analysis. PDGFRα was found to be abundantly 
expressed in fibroblasts (HFF and MRC5) but not detectable in epithelial cells (293 and 
ARPE-19) and EC (HUVEC) (Figure 27), coinciding with the observation that in cell culture, 
only fibroblasts are susceptible for HCMV lacking the pentameric complex and expressing 
only the gH/gL/gO complex [93, 94]. Additionally, this fits the observation that gO-Fc 
specifically binds to HFF, but not to HUVEC (Figure 12). 
 
 
Figure 27: PDGFRα levels in different cell types. 
Cell extracts were analyzed for PDGFRα levels or as a loading control β-actin by Western blot analysis using 
the corresponding first antibodies and a peroxidase-conjugated goat anti-mouse IgG as second antibody. 
 
Although there seems to be a correlation between expression levels of PDGFRα and  
susceptibility to binding of gO-Fc protein to cell surfaces (Figure 9), TB40-UL131stop 
infection of different cell types may also be shaped by cell type-specific costimulatory cell 
surface proteins which affect HCMV entry. To directly determine in one specific cell line that 
there is a correlation of PDGFRα levels and HCMV entry, 293 cells, which do not express 
detectable levels of PDGFRα (Figure 27, Figure 28a and Figure 28b), were transfected with 
a plasmid expressing PDGFRα. 
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Figure 28: Over-expression of PDGFR𝛂 in 293 cells. 
293 cells were transfected with pCMV-PDGFRα or a vector control (pCR3.1). a) lysates of cells collected 24 h 
and 48 h after transfection were analyzed by Western blot using a mouse-anti-PDGFRα antibody and a 
peroxidase-conjugated goat anti-mouse IgG. b. Transfected cells were fixed at 24 h after transfection, and 
either stained with Hoechst 33258 to visualize nuclei or by indirect immunofluorescence staining using a 
mouse-anti-PDGFRα antibody and an Alexa Fluor-488-conjugated goat anti-mouse IgG. Scale bar, 200 μm. 
 
Control- and PDGFRα- transfected cells were infected with TB40-Luc, TB40-UL131stop-
Luc or TB40-∆gO-Luc. Infections were adjusted prior infection. TB40-UL131stop-Luc, 
lacking the pentameric complex can hardly infect epithelial cells which is reflected in Figure 
29a. TB40-∆gO-Luc amounts were adjusted to result in a infection of mock-transfected 293 
cells comparable TB40-Luc. Over-expression of PDGFRα strongly enhanced infection with 
both TB40-Luc and TB40-UL131stop-Luc viruses (Figure 29a). In contrast, over-expression 
of PDGFRα had no impact on infection of TB40-ΔgO-Luc virus (Figure 29b). Again, these 
data suggest that gO-dependent entry of HCMV correlates with PDGFRα levels in host 
cells. 
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Figure 29: PDGFR-overexpression enhances HCMV infection in a gO-dependent manner. 
293 cells were transfected with pCMV-PDGFRα (Sino Biological Inc.) or a vector control (pCR3.1), and 2 days 
later infected with a) TB40-Luc or TB40-UL131stop-Luc or b) TB40-Luc or TB40-∆gO-Luc. Cells were lysed at 
24 h.p.i and analyzed by a luciferase assay. Shown are means +/- S.E.M. of 3 independent experiments done 
in triplicates. Unpaired student's t-test was performed for statistical analysis. (n.s. denotes p>0.05; *** denotes 
p<0.001) 
 
3.2.4 Inhibition of HCMV infection with PDGFRα ligand 
Several natural ligands of PDGFRα bind to its extracellular domain with high affinity. 
Therefore, they are good candidates to further confirm a gH/gL/gO-PDGFRα interaction. To 
test whether PDGF-BB, a ligand of PDGFRα, can interfere with HCMV entry into 
fibroblasts, HFF were preincubated with PDGF-BB, and then infected with TB40-Luc, TB40-
UL131stop-Luc or TB40-∆gO-Luc in the presence of PDGF-BB. To inactivate not 
penetrated virions, cells were washed 3 times with PBS, pH 3.0. Twenty four h p.i, infection 
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was quantified by a luciferase assay. Infection of HFF by TB40-Luc was about 50 % 
reduced, TB40-UL131stop-Luc infection was about 30 % reduced, and TB40-∆gO-Luc 
infection was not affected (Figure 30). Thus again, only gH/gL/gO-positive HCMV showed a 
PDGFRα-dependent infection pattern. 
 
 
Figure 30: PDGF-BB inhibits TB40-Luc and TB40-UL131stop-Luc but not TB40-∆gO-Luc entry into 
HFF. 
HFF cells are preincubated with PDGF-BB or as a control 5% DMEM for 15min and then infected with TB40-
Luc, TB40-UL131stop-Luc and TB40-∆gO-Luc in the absence (controls) or presence of PDGF-BB. Infection 
was performed with  centrifugal enhancement followed by 1 h incubation at 37 ℃. After infection, cells were 
washed 3 times with PBS (pH 3.0) to inactivate and remove free virus and cell surface-bound virus and then 
cultivated with medium containing PAA. 24 h p.i., cells were lysed and analyzed by a luciferase assay. Shown 
are means +/- SD of one experiment performed in triplicates.  
 
A previous study has suggested that activation of PDGFRα is required for HCMV infection 
[72]. Thus, pre-stimulation of host cells with a ligand of PDGFRα which activates PDGFRα 
might promote HCMV entry into host cells. To investigate this, cells were preincubated with 
PDGF-BB and infected in the absence of PDGF-BB. Infection was slightly elevated 
independent whether virions contained gH/gL/gO complex or not (Figure 31). If activation of 
PDGFRα was essential for gH/gL/gO- or gH/gL/pUL(128, 130, 131a)-dependent entry, one 
would have expected a stronger enhancement of infection. 
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Figure 31: PDGF-BB stimulation has hardly any effect on TB40-Luc, TB40-UL131stop-Luc and TB40-
∆gO-Luc infections of HFF. 
HFF cells are preincubated with PDGF-BB or as a control 5% DMEM for 15min and then infected with TB40-
Luc, TB40-UL131stop-Luc and TB40-∆gO-Luc in the absence of PDGF-BB. Infection was performed with 
centrifugal enhancement followed by 1 h incubation at 37 ℃. After infection, cells were washed 3 times with 5% 
DMEM to remove free virus and then fed with medium containing PAA. At 24 h p.i., cells were lysed and 
analyzed by a luciferase assay. Shown are means +/- SD of one experiment performed in triplicates. 
 
It has been reported before that imatinib mesylate, a tyrosine kinase inhibitor, can 
substantially inhibit HCMV infection by blocking the kinase activity of PDGFRα and 
abolishing downstream activation pathways in U87 glioma and human embryonic lung 
(HEL) cells [72]. In contrast, a second study found that the effect of imatinib mesylate on 
HCMV entry was not specific for HCMV but could also be observed for HSV-1, and thus 
very likely resulted in a general down-regulation of cellular signaling pathways [74]. To 
decide whether imatinib mesylate has a specific effect on HCMV entry and whether this 
effect is gO-dependent, HFF were pretreated with imatinib mesylate and then infected with 
TB40-Luc, TB40-UL131stop-Luc or TB40-∆gO-Luc. Virus entry was quantified by 
evaluating infection using a luciferase assay. Both TB40-Luc and TB40-UL131stop-Luc 
were slightly inhibited, while no impact was observed for TB40-∆gO-Luc infection (Figure 
32). This could indicate that activation might play a role in gH/gL/gO-dependent entry. 
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Figure 32: Imatinib mesylate inhibits TB40-Luc and TB40-UL131stop-Luc but not TB40-∆gO-Luc 
infections of HFF. 
HFF cells were pretreated with imatinib mesylate or as a control 5% DMEM for 1 h and then infected with 
wildtype TB40-Luc, TB40-UL131stop-Luc or TB40-∆gO-Luc for 90 min in the presence of imatinib mesylate. 
Free virus was removed by washing the cells 3 times with 5% DMEM. Cells were cultured in fresh medium 
containing PAA and imatinib mesylate. At 24 h p.i., cells were lysed and analyzed by a luciferase assay. 
Shown are means +/- SD of one experiment performed in triplicates. 
 
In summary, data reveal that gH/gL/gO-dependent entry and PDGFRα-dependent entry are 
congruent. PDGFRα thus very likely is the entry receptor used by gH/gL/gO. The restricted 
numbers of experiments studying the role of PDGFRα phosphorylation in gH/gL/gO-
dependent entry do not yet allow a final conclusion whether gH/gL/gO-dependent entry is 
phosphorylation-dependent. 
 
 
3.3 The role of the gH/gL/gO complex in MCMV infection 
The infection of mice with murine cytomegalovirus (MCMV), serves as a model for the 
human HCMV infection. MCMV encodes functional homologues of the HCMV gH/gL/gO 
and gH/gL/pUL(128, 130, 131a) complexes, namely a gH/gL/gO (m74) complex [165] and a 
gH/gL/MCK-2 (m131/129) complex [166]. 
 
3.3.1 The role of deletion of gO in MCMV infection of different cell types 
Infection capacities of HCMV for different cell types are gH/gL/gO dependent (Figure 8). To 
find out whether ΔgO mutants of MCMV also show cell type specific changes in infection 
TB
40
-Lu
c
TB
40
-13
1s
top
-Lu
c
TB
40
-Δ
gO
-Lu
c
0.0
5.0×105
1.0×106
1.5×106
2.0×106
2.5×106
5%DMEM
Imatinib mesylate (100nM)
Lu
ci
fe
ra
se
 (R
LU
)
 Results   
     70 
capacities, MCMV infection of different cell types was analyzed. For all experiments, MCMV 
3.3WT which is a BAC clone of the MCMV strain Smith (pSM3fr-MCK-2fl) [185] and 
mutants therefore were used. Δm74 is a gO-deletion mutant lacking the 532 N-terminal 
base pairs of m74 and m74stop is a gO-stop mutant with a stop cassette at nucleotide 
position 120 nt [165]. ΔgO-gOtrans virions are phenotypically WT-like virions carrying 
gH/gL/gO complexes in the envelope. They were generated by propagation of Δm74 virions 
in NIH3T3 cells expressing gO [166]. Primary embryonic fibroblasts (MEF), a fibroblast cell 
line (NIH3T3), lung epithelial cells (TCMK-1), EC (MHEC-5T), and macrophages (ANA-1) 
were infected with wildtype MCMV (3.3WT), ΔgO mutants (Δm74 and m74stop), and a gO-
transcomplementated ΔgO virus (ΔgO-gOtrans). For all viruses, infection was normalized to 
infection of MEF which was arbitrarily set to 1. Compared to WT virus, both ΔgO mutants 
showed reduced infection capacities for NIH3T3 and TCMK-1. Transcomplementation 
reverted this phenotype (Figure 33a). Infection of ANA-1 was not affected by deletion of gO 
(Figure 33b). Strikingly, infection of MHEC-5T was enhanced by deletion of gO. This 
enhancement was not completely reversed by transcomplementation (Figure 33a), a 
phenomenon that might due to non-wildtype gO levels in transcomplemented virions. 
 
 
Figure 33: Comparison of the relative infection capacities of MCMV 3.3WT, ΔgO mutants and ΔgO-
gOtrans for different cell types in culture. 
MEF, NIH3T3, TCMK-1, MHEC-5T and ANA-1 cells were infected with 3.3WT, Δm74, m74stop or ΔgO-
gOtrans. Infection capacities were determined (a) 4h p.i. by indirect immunofluorescence (data from Ilija Brizic) 
or (b) 16 h p.i. by intracellular FACS analysis specific for MCMV immediate-early 1 protein (ie1). Bars 
represent means +/- SD of at least three independent experiments. Unpaired student's t-test was performed 
for statistical analysis. (n.s. denotes p>0.05) 
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In conclusion, MCMV lacking gO shares infection patterns with gO-null HCMVs when 
infection of different cell types all compared. Viruses lacking gH/gL/gO show low infection 
capacities for epithelial cells and fibroblasts and a relatively increased infection capacity for 
EC. 
 
3.3.2 MCMV produced in MEF or NIH3T3 cells have different infection capacities 
MEF and NIH3T3 cells are two extensively used cell types for production of MCMV in cell 
culture. Thus, it is of high importance to study whether viruses produced from the two cell 
types have similar qualities. 
 
When comparing the infection capacities of WT MCMV either derived from MEF or NIH3T3 
cells on macrophages, MEF-derived virus showed a lower capacity to infect ANA-1 than 
NIH3T3-derived virus (Figure 34). A reduced infection capacity for ANA-1 cells has also 
been observed for MCMV lacking MCK-2 [166]. 
 
 
Figure 34: Comparison of macrophage infection capacities of WT MCMV derived from MEF or NIH3T3 
cells. 
MCMV derived from MEF (3.3WT-MEF) or NIH3T3 cells (3.3WT-NIH3T3) were used to infect ANA-1. Infection 
capacities were determined 16 h p.i. by intracellular FACS analysis specific for MCMV ie1 protein. Infection 
was normalized to the number parallely of infected MEF. Shown are means +/- SD of one representative 
experiment out of 2 assayed in triplicates. 
 
ANA-1
3.3
WT
-M
EF
3.3
WT
-N
IH
3T
3
0.0
0.5
1.0
1.5
R
el
at
iv
e 
in
fe
ct
io
n 
ca
pa
ci
ty
 Results   
     72 
To further investigate the infection capacities of MEF- and NIH3T3-derived virus, infection 
of additional cell types was analyzed. MEF, NIH3T3, TCMK-1 and MHEC-5T cells were 
infected with supernatant viruses derived from MEF and NIH3T3 cells. Infection capacities 
were evaluated by staining for MCMV ie1 protein. MEF-derived and NIH3T3-derived MCMV 
showed similar infection capacities for NIH3T3 and TCMK-1 cells. NIH3T3-derived virus 
showed a higher relative infection capacity for EC than MEF-derived virus (Figure 35). 
 
For HCMV, it has also been reported that different cell types produce virus progenies which 
differ in their infection capacities for different cell types. This has been attributed to different 
ratios of gH/gL complexes in virions [102, 122]. 
 
 
Figure 35: Comparison of infection capacities of supernatant virus-derived from MCMV-infected MEF 
and NIH3T3 cells. 
MCMV derived from MEF (3.3WT-MEF) or NIH3T3 cells (3.3WT-NIH3T3) were used to infect MEF, NIH3T3, 
MHEC-5T or TCMK-1 cells. Infection capacities were determined 4h p.i. by indirect immunofluorescence 
specific for MCMV ie1 protein. Infection was normalized to the number of parallely infected MEF. Shown are 
means +/- SD of one representative experiment out of two assayed in triplicates. 
 
To exclude that the observed discrepancy between MEF- and NIH3T3-derived virus was 
not caused by the way virus was collected, different virus preparation methods: i) 
precleared supernatant virus, ii) pelleted virus and iii) sucrose cushion-purified virus. Pellets 
were prepared by high speed centrifugation of supernatants of infected MEF or NIH3T3 
cells. For preparation of sucrose cushion-purified virus, those pellets are further purified 
through 15 % sucrose cushions. All three virus preparations showed a discrepancy for the 
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infection capacity for EC (Figure 35, 36a and 36b), although it appeared less pronounced 
for the sucrose-cushion purified viruses (Figure 36b). 
 
 
Figure 36: Comparison of infection capacities of virus pellets and sucrose-cushion purified virions. 
Virus pellets (a) and sucrose-cushion-purified viruses (b) derived from MEF (3.3SN-MEF) or NIH3T3 cells 
(3.3SN-NIH3T3) were used to infect MEF, NIH3T3, MHEC-5T or TCMK-1 cells. Infection capacities were 
determined 4h p.i. by indirect immunofluorescence analysis specific for MCMV ie1 protein. Infection was 
normalized to the number of parallely infected MEF. Shown are means +/- SD of one representative 
experiment out of two assayed in triplicates. 
 
To test whether virus produced by other cell types also show discrepant infection 
capacities, virus produced from TCMK-1, MHEC-5T and fibroblasts was tested on MHEC-
5T and TCMK-1. Only virus produced from NIH3T3 has a higher infection capacity for 
MHEC-5T cells (Figure 37).  
 
The discrepancy between MEF- and NIH3T3-derived virus might be due to different ratios 
of gH/gL/gO and gH/gL/MCK-2 complexes. To analyze this, one would need to compare the 
gO and MCK-2 levels of those virus particles. However, lack of an antibody against MCMV 
gO hinders further investigation of this issue. Thus, the next step to address this issue 
would be to produce an antibody against MCMV gO. 
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Figure 37: Comparison of infection capacities of supernatant virus from MCMV-infected MEF, MHEC-
5T and TCMK-1 cells. 
MCMV from MEF, NIH3T3, MHEC-5T or TCMK-1 cells were used to infect MEF, NIH3T3, MHEC-5T or 
TCMK-1 cells. Infection capacities were determined 4h p.i. by indirect immunofluorescence analysis specific 
for MCMV ie1 protein. Infection was normalized to the number of parallely infected MEF. Shown are means 
+/- SD of one experiment assayed in triplicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MHEC-5T TCMK-1
3.3
WT
-M
EF
3.3
WT
-N
IH
3T
3
3.3
WT
-M
HE
C-
5T
3.3
WT
-TC
MK
-1
3.3
WT
-M
EF
3.3
WT
-N
IH
3T
3
3.3
WT
-M
HE
C-
5T
3.3
WT
-TC
MK
-1
0.0
0.2
0.4
0.6
0.8
1.0
R
el
at
iv
e 
in
fe
ct
io
n 
ca
pa
ci
ty
Discussion 
     75 
4 Discussion 
 
HCMV is highly prevalent worldwide, causing morbidity and mortality in 
immunocompromised individuals and birth defects after congenital infection [13]. Up to now, 
there is still no approved vaccine against HCMV available on the market and the treatments 
are restricted. Viral infection starts with successful entry into host cells which relies on 
interactions between host cell receptors and viral envelope glycoprotein complexes. The 
specificity of the virus-receptor interaction is a pivotal determinant of virus cell tropism and 
host range. Therefore, investigation of host cell receptors for HCMV entry may contribute to 
the development of vaccines and anti-virals. In the last three decades, many studies aimed 
at identifying and characterizing host cell receptors for HCMV. However, so far, none of the 
reported proteins could be confirmed to be functional entry receptors.  
 
In cell culture it has been shown that cell type-specific HCMV infection and thus recognition 
of cell-type-specific receptors are promoted by the envelope glycoprotein complexes 
gH/gL/gO and gH/gL/pUL(128, 130, 131a) [50, 68, 118]. 
 
This study concentrated on the identification of a host cell receptor for gH/gL/gO and the 
role of gH/gL/gO in HCMV infection in cell culture. Previous studies have shown that gO-
null mutants produced only small plaques in fibroblast culture and that titers of gO-null 
progeny virus were 1000 fold lower than those of wildtype HCMV [107]. gO has also been 
reported to contribute to HCMV release by taking part in the secondary envelopment of 
virions [106]. Cellular receptors of the gH/gL/gO complex are considered to be fibroblast-
specific [68]. Additionally, a general role of the gH/gL/gO complex in enhancing infection of 
all cell types was reported [104]. Recently, a study of MCMV mutants in mice specified an 
essential role for gO in entry into first target cells during the primary infection in vivo [109]. 
 
 
4.1 A switch of tools - from gO-Fc fusion proteins to virus particles for identification 
of the cellular receptor of the gH/gL/gO complex 
Utilization of IgG-Fc fusion proteins to fish protein binding partners and to purify them by 
using protein A or G beads is a widely used method for identification of viral receptors [53, 
189, 193, 194]. The starting point here was to produce an IgG Fc-fused HCMV gO protein 
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(gO-Fc) as a tool to investigate the role of gO in HCMV infection and to identify a host cell 
receptor for the gH/gL/gO complex. To avoid an Fc-specific interaction with Fcγ-binding 
proteins in the viral envelope or on host cells [195, 196], mouse IgG2b-Fc, which has been 
shown not to bind to HCMV Fc receptors, [197] was used as a fusion tag.  
 
The gO-Fc protein specifically bound to cells whose infection is predominantly dependent 
on the gH/gL/gO complex, but not to cells whose infection is mainly driven by the 
gH/gL/pUL(128-131a) complex. When testing whether gO-Fc could compete with binding of 
HCMV virions to HFF and consequently inhibit infection, no block of infection could be 
observed. Several reasons might account for that: 1) The yield of gO-Fc was low and 
preparation only with 3-16 μg/ml could be produced. For comparison, EBV gp42-Fc fusion 
protein could inhibit EBV infection of host cells through the EBV gH/gL/gp42 complex only 
when the gp42-Fc preparations showed concentrations of 10 μg/ml or more [53]. Therefore, 
the amount of HCMV gO-Fc might not have been sufficient to block all receptors on the 
surface of HFF. 2) Binding of gO-Fc on cell surfaces was temperature- and detergent-
sensitive and could be easily reversed, reflecting a very weak interaction between the gO-
Fc protein and its binding partner on HFF. If the gH/gL/gO complex in virions bound with a 
much higher affinity to the cellular receptor than gO-Fc protein, it would substitute the gO-
Fc protein. This could also be the reason why in coprecipitation experiments using gO-Fc 
no cellular binding partner for gO could be deleted. Hence, an alternative strategy was used 
to identify the cellular receptor for the gH/gL/gO complex: coincubation of fibroblasts with 
HCMV virions followed by precipitation of gH and proteins bound to gH. To avoid 
precipitation of proteins interacting with the gH/gL/pUL(128, 130, 131a) complex, TB40-
UL131stop, an HCMV mutant lacking the gH/gL/pUL(128, 130, 131a) complex, was used. 
 
 
4.2 PDGFRα as a binding partner for gH/gL/gO 
To date, a number of different host cell surface proteins have been shown to enhance 
HCMV infection of cells in culture. Previous studies have already proposed a connection 
between PDGFRα and HCMV entry. It has been observed that binding of HCMV to host 
cells induced phosphorylation of PDGFRα and activation of downstream molecules [72]. 
Knockdown of PDGFRα, or treatment with a PDGFRα ligand (PDGF-AA), a tyrosine-kinase 
inhibitor (imatinib mesylate), or a PDGFRα-neutralizing antibody all inhibited HCMV 
infection. Additionally, a gB-PDGFRα interaction was observed in cells expressing 
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recombinant gB [72]. Therefore, it has been claimed that activation of PDGFRα plays a vital 
role in mediating HCMV entry [72]. Yet, another study contested this claim based on the 
observation that although overexpression of PDGFRα highly enhanced HCMV infection, 
virus entry was not affected by preincubating cells with anti-PDGFRα antibodies, PDGF-AA, 
or by knockdown of PDGFRα [74]. 
 
Here, it could be shown that PDGFRα is indeed an entry receptor for HCMV and that not 
gB, but gH/gLgO is the binding partner on virions. To precipitate specific cell surface 
proteins binding the gH/gL/gO complex, TB40-UL131stop virions were mixed with cell 
surface-biotin-labeled HFF. Two approaches were used, 1) virions and HFF cells were 
lysed independently and then mixed, or 2) virions and HFF were coincubated and then cells 
and bound virions were lysed. Precipitation of gH from these lysates resulted in co-
precipitation of gH, gO and a cellular 200 kDa biotinylated protein, indicating a successful 
precipitation of a specific cell surface protein. Subsequent mass spectrometry analysis of 
this protein identified it as PDGFRα. Using IgG Fc-fused PDGFR protein, gO, gH and gB 
could be co-precipitated by PDGFRα-Fc protein but not by PDGFRβ-Fc, demonstrating a 
highly specific interaction with PDGFRα. PDGFRα could also be co-precipitated by using 
the gO-Fc protein, indicating that PDGFRα directly interacts with gO. 
 
 
4.3 gB and PDGFRα 
The envelope glycoproteins gB and gH/gL are conserved within the family of Herpesviridae. 
They form the core fusion complex necessary for viral entry into host cells [45]. HCMV gB is 
essential for virion fusion with the host cell plasma membrane and cell-to-cell spread of 
virus [198], but it is not involved in recognition of entry receptors [75]. It has recently been 
reported that HCMV gB interacts with gH/gL to form stable gH/gL/gB complexes that are 
incorporated into virions independent of membrane fusion or receptor binding [191]. Here, a 
Co-IP of gB, gH and PDGFRα was achieved by using either the PDGFRα-Fc protein or 
anti-gH antibody to precipitate protein complexes. A previous study had shown that 
PDGFRα binds to recombinant HCMV gB [72]. This raised the question whether the Co-IP 
of gH, gO, PDGFRα and additionally gB reflect an interaction of the gH/gL/gO complex with 
gB bound to PDGFRα, or interactions of gH/gL/gO with PDGFRα and independently also 
with gB, or whether gB and gH/gL/gO both independently bind to PDGFRα. To test this, Co-
IP experiments using virus lysates of an HCMV mutant lacking gH/gL/gO should be 
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performed to test whether anti-gH antibody and recombinant PDGFRα-Fc protein 
precipitate gB also in the absence of gO. To test whether anti-gB antibodies could also co-
precipitate gH and/or PDGFRα, several anti-gB antibodies were used to precipitate binding 
partners of gB, however, only gB was precipitated. This very likely reflects that the anti-gB 
antibodies used bind to a gB epitope which is involved in the formation of gB-gH 
complexes. In line with this observation, a previous study using a gB-specific antibody also 
failed to precipitate recombinant gH/gL/gB complexes formed in transfected cells [67]. 
 
Overexpression of gB in host cells can overcome the fusion deficiency of gB-null 
expressing virus [75], suggesting that gB is a fusion promotor rather than a receptor-binding 
protein. In summary, all data suggest that the co-precipitation of gB and PDGFRα is 
mediated by gH. In accordance with previous studies, a possible model of HCMV entry 
might be that the gH/gL complexes recognize different receptors on different cell types, for 
instance, gH/gL/gO recognizes PDGFRα, and subsequently activate gB to initiate fusion 
[75]. 
 
 
4.4 gO-dependent infection correlates with PDGFRα-dependent infection 
It has been shown that HCMV infection of fibroblasts is dependent on the gH/gL/gO 
complex [68, 107]. PDGFRα has been reported to be essential for efficient HCMV infection 
of fibroblasts [72]. Overexpression of PDGFRα in different host cell types markedly boosted 
entry of both wildtype HCMV and mutants lacking gH/gL/pUL(128, 130, 131a) [72, 74, 199], 
suggesting that gH/gL/gO contributes to PDGFRα-enhanced entry. HCMV enters 
fibroblasts through direct fusion with the plasma membrane at neutral pH [21], whereas it 
enters epithelial cells and EC through macropinocytosis which involves internalization of 
virions into endosomes and subsequent low pH-dependent fusion with endosomal 
membranes [22, 50]. When entering epithelial cells overexpressing PDGFRα, virus entry 
switched to pH-independent fusion [74]. 
 
4.4.1 Soluble PDGFRα or PDGFRα ligand can block infection of HCMV expressing gO 
A convenient and reliable strategy to evaluate HCMV infection has been established by 
using luciferase-labeled HCMVs [122]. These luciferase-expressing viruses were used here 
for blocking experiments. Preincubating of soluble PDGFRα protein with virions or PDGFRα 
ligand PDGF-BB with host cells efficiently blocked entry of gH/gL/gO-positive HCMV into 
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HFF, while the same treatment did not affect TB40-ΔgO-Luc entry. This suggests that the 
inhibition relies on a gH/gL/gO-PDGFRα interaction. Intriguingly, the treatment with soluble 
PDGFRα protein could completely block infection of TB40-UL131stop-Luc, yet, when 
wildtype TB40-Luc was used a residual infection was observed. This could be explained 
that infection with the UL131stop mutant completely relies on the gH/gL/gO complex 
whereas wildtype HCMV infection partially depends on gH/gL/pUL(128, 130, 131a). The 
observed low residual infection (2.2%) of TB40-Luc indicates that HCMV infection is 
predominantly dependent on the gH/gL/gO complex. 
 
4.4.2 The infection capacity of HCMV correlates with the abundance of PDGFRα in 
host cells 
It has been shown that the binding capacity of HCMV virions for fibroblasts is much higher 
than for other cell types tested [40, 41]. Combined with the observation that fibroblasts 
show abundant PDGFRα level in contrast to epithelial cells and EC. This indicates a 
correlation between the infection capacity of HCMV and the abundance of PDGFRα in host 
cells. In this study, gO was found to directly interact with PDGFRα. Additionally, 
recombinant gO-Fc protein bound much better to fibroblasts than to EC which correlates 
with the PDGFRα level of these cells. Overexpression of PDGFRα in different cell types 
(including epithelial cells) promoted entry of both wildtype HCMV and HCMV lacking the 
pentameric complex [72, 74]. In line with that, infection of 293 cells transfected with a vector 
expressing PDGFRα showed an enhanced entry of gO-positive HCMV when compared to 
non-transfected 293 cells, supporting that enhancment of HCMV infection is gH/gL/gO-
dependent and correlates with the abundance of cellular PDGFRα. It has been shown in 
cells transfected with vectors expreeing gB and gH/gL that overexpression of PDGFRα did 
not enhance gB, gH/gL-induced cell-cell fusion [74], indicating that PDGFRα-enhanced 
entry was not dependent on gB or gH/gL dimer. All these data support PDGFRα as a bona 
fide entry receptor for the HCMV gH/gL/gO complex. 
 
4.4.3 The gH/gL/gO complex shapes HCMV entry in cell culture 
Previous reports revealed that HCMV spread in EC cultures exhibits a cell-associated focal 
pattern and is gH/gL/pUL(128, 130, 131a)-dependent, while spread in fibroblast cultures is 
homogeneous and driven by supernatant virus [122]. Interestingly, the spread pattern of 
gO-null virus in fibroblast cultures was strictly cell associated and produced only small 
plaques [106, 122]. This suggests supernatant-driven spread in fibroblast cultures is driven 
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by gH/gL/gO complex. In this study, infection of cells with preincubation of virus particles 
with recombinant PDGFRα completely blocked virus expressing only the gH/gL/gO 
complex, whereas preincubation of virus expressing both gH/gL complexes could not be 
blocked completely. In addition, incubation of PDGFRα protein with HCMV infected cells 
restricted virus spread in fibroblasts and produced smaller plaques, whereas the same 
treatment had no effect on virus spread in EC which is driven by the gH/gL/pUL(128, 130, 
131a) complex. This spread pattern of HCMV in fibroblast culture was similar to spread of 
gO-null virus. Specifically, an antibody against the pentameric complex halted virus spread 
in EC but had no effect on virus spread in fibroblasts which express abundant PDGFRα. 
Coupled with previous data, it can be concluded that HCMV infection of cells with free virus 
is mainly driven by the gH/gL/gO complex, provided the cells abundantly express PDGFRα 
on their surface. Virus spread in EC cultures neither depends on PDGFRα nor on the 
gH/gL/gO complex, but depends on the gH/gL/pUL(128, 130, 131a) complex.  
 
In summary, the relative abundances of viral gH/gL/gO and cellular PDGFRα shape the cell 
tropism of HCMV. For instance, for HCMV particles with high levels of gH/gL/gO, the 
PDGFRα level of target cells will be the major determinant for cell tropism. The 
gH/gL/pUL(128, 130, 131a) complex determines HCMV entry into cells which scarcely 
express PDGFRα. 
 
This should be taken into account when characterizing the HCMV cell tropism in cell 
culture. Cell culture conditions [200, 201] and transforming antigens [199] may alter the 
cellular expression level of PDGFRα and thus affect the infection capacities of HCMV for 
these cells. For example, expression of PDGFRα could be downregulated by suramin 
treatment or 3D-culture and upregulated by interleukin-1 β [200, 201]. In addition, 
expression of oncogenic alleles like simian virus 40 T antigen in human cells reduced the 
abundance of PDGFRα and thus inhibited HCMV infection [199]. Thus, due to the 
complexity and dynamic tendency, it is difficult to predict the HCMV in vivo tropism from cell 
culture studies. 
 
 
4.5 PDGFRα-dependent entry ans PDGFRα activation 
Virus entry can trigger receptor-mediated signaling in host cells. For HCMV, activation of 
the PI3K and MAPK signaling pathway has been reported in a number of different cell types 
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including fibroblasts [71, 139], monocytes [202, 204] and EC [203]. It has been reported 
that gH/gL/pUL(128, 130, 131a) is required for activation of the integrin/Src/paxillin pathway 
required for entering monocytes [204]. HCMV gB and gH are both considered to be 
involved in signaling pathways by binding cell surface integrins and EGFR [139, 204, 205]. 
A prerequisite for activation of PDGFRα is homodimerization or heterodimerization with 
PDGFRβ [206]. Phosphorylation of PDGFRα by HCMV has been detected upon HCMV 
infection by using an antibody that recognizes the heterodimeric PDGFRα/β complex [72, 
207]. By using the tyrosine kinase inhibitor imatinib mesylate, phosphorylation of PDGFRα 
by HCMV in human embryonic lung fibroblasts (HELs) was inhibited [72]. Another study 
demonstrated that imatinib mesylate inhibited not only HCMV but also HSV-1, suggesting a 
non-specific role in inhibiting on herpesvirus infection [74]. Here, HCMV infection of HFF 
could only be slightly inhibited with imatinib mesylate. In summary, one study showed that 
imatinib mesylate was able to block phosphorylation of PDGFRα but it was not tested 
whether imatinib mesylate could also block HCMV infection [72], whereas the other study 
showed that HCMV infection of ARPE-19 cells could be inhibited by imatinib mesylate [74]. 
Thus, the observed discrepancy might due to cell type-specific PDGFRα-activation 
patterns. 
 
 
4.6 HCMV infection and its association with glioblastoma or coronary heart disease 
HCMV has been proposed to play a role in the pathogenesis of glioblastoma more than a 
decade ago. Based on the observation that viral proteins and nucleic acids of HCMV have 
been occasionally detected in tumor cells [208], a debate has been started whether HCMV 
could serve as a therapeutic target for treatment of glioblastoma. It has also been claimed 
that HCMV infection results in the formation of atherosclerosis as several HCMV proteins or 
DNA could be detected in various cells of atherosclerotic vessel walls [209]. Both the 
atherosclerotic lesions and the glioblastoma express high levels of PDGFRα, suggesting 
that they might rather serve as good targets for HCMV infection than being caused by 
HCMV. Supporting this, a recent clinical trial using valganciclovir as an adjuvant therapy for 
glioblastoma failed to prove a beneficial effect on either tumor growth or overall survival 
[210]. Thus, the correlation between HCMV and atherosclerosis and glioblastoma may just 
reflect a PDGFRα-driven susceptibility to HCMV infection. 
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4.7 The gH/gL/gO-PDGFRα complex 
As PDGFRα is used by different strains of HCMV for entry [72, 74, 199], the binding site of 
gO very likely is within the most conserved region of gO, aa 100 to aa 270 [102]. One can 
imagine several options how the gH/gL/gO complex binds to PDGFRα: i) PDGFRα 
possesses 5 immunoglobulin-like (IgG-like) repeats in its extracellular domain [211] and 
PDGFs bind to the second IgG-like region of PDGFRα [211]. It has been reported that the 
PDGFRα ligand PDGF-AA competes with HCMV and causes significant inhibition of HCMV 
entry into fibroblasts [72]. Accordingly, in this thesis, the PDGFRα ligand PDGF-BB was 
found to be able to interfere with HCMV entry into fibroblasts. These data suggest that the 
gO binding site on PDGFRα could be within or overlap with the second IgG-like region of 
PDGFRα. ii) Another potential mechanism of the ligand-dependent block might be that the 
ligand-induced dimerization of PDGFRα interferes with the binding of gH/gL/gO. In other 
words, gH/gL/gO might only bind PDGFRα in a monomeric form. 
 
 
4.8 A model for gH/gL/gO-dependent entry of HCMV 
It has previously been shown that HCMV infection of fibroblasts depends on the gH/gL/gO 
complex and that fibroblasts possess a receptor for gH/gL/gO [68]. Here, it could be 
demonstrated that fibroblasts abundantly express PDGFRα which is recoginized by 
gH/gL/gO, and are therefore a dominant target for HCMV. Current data indicate that HCMV 
gB acts as a fusion trigger which is required for entry into all cell types [50] rather than a 
receptor-binding protein [75]. It has been reported that gB is able to bind integrins and 
induce subsequent integrin signaling which has a crosstalk with PDGF signaling [70, 139, 
141]. This could at least partially explain the observed activation of cellular signaling 
pathways upon HCMV infection. In addition, gB can bind gH during entry [97]. Collectively, 
this supports a model of HCMV entry initiated by an interaction of PDGFRα and gH/gL/gO 
(Figure 38). HCMV gH/gL/gO interacts with PDGFRα on the cell surface upon virion 
attachment, which may or may not induce the phosphorylation of PDGFRα. A subsequent 
conformational change of the gB-gH/gL/gO complex moves gB closer to the host cell 
membrane. There, gB induces direct fusion of virion membrane with the plasma membrane 
(Figure 38). 
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Figure 38: Model of PDGFRα-mediated HCMV entry with cell free virus. 
gH/gL/gO binds to PDGFRα upon attachment of virions to the cell surface. Depending on the cell type, this 
interaction may cause phosphorylation and dimerization of PDGFRα. The gH/gL/gO-PDGFRα interaction then 
induces a conformational change of the the gB-gH/gL/gO complex and moves gB closer to the cell 
membrane, which subsequently induces direct fusion between virus envelope and the plasma membrane. 
 
 
4.9 MCMV as a model to study the gH/gL/gO complex 
MCMV serves as a model for HCMV and its infection resembles in many aspects of HCMV 
infection, including cell and organ tropism, pathogenesis during acute infection, 
establishment of latency, and reactivation after immunosuppression [152, 212, 213]. MCMV 
also forms two gH/gL complexes, gH/gL/m74 which is functionally homologous to HCMV 
gH/gL/gO, and gH/gL/MCK2 [165, 166]. 
 
4.9.1 Infection properties of MCMV gO-null mutants 
Previous studies revealed that m74 knockout mutants of MCMV exhibit spread patterns in 
cell culture which are comparable to spread patterns of gO knockout mutants of HCMV 
[122]. When comparing the infection capacities of m74-null virus on different cell types in 
cell culture, deletion of m74 reduced virus entry into fibroblasts and showed a relative 
enhancement of entry into EC [109], infection properties which gO-null mutants of HCMV 
also exhibit [122]. Yet, m74-null MCMV showed a pronounced reduction of entry into 
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epithelial cells [109], whereas gO-null HCMV exhibited an enhancement of entry into 
epithelial cells. These distinct infection properties of HCMV and MCMV in cell culture might 
rather be cell line-specific or dependent on culture conditions rather than being cell type-
specific. 
 
4.9.2 Infection capacities of MCMV progenies derived from different cell types 
Here, it was described that MCMV progenies from two types of fibroblasts, MEF and 
NIH3T3, had different infection capacities for different cell types. NIH3T3-derived virus 
showed a relatively higher capacity to infect EC and macrophages than MEF-derived virus. 
Analysis of different MCMV progenies from MEF, NIH3T3, TCMK-1 and MHEC-5T also 
emphasized that NIH3T3-derived progenies infect EC more efficiently than MCMV 
progenies from other cell types. Cell-type specific differences of virus progenies have also 
been found for HCMV. They have been shown to correlate with the relative ratios of the 
gH/gLgO and gH/gL/pUL(128, 130, 131a) complexes in virions [122]. These ratios are 
determined by the cell type in which the virus is propagated and they affect the pattern of 
HCMV tropism [122]. The mechanism for MCMV may be similar and the relative 
abundances of the MCMV gH/gL complexes in virions may also determine the cell tropism 
of MCMV (Figure 39). 
 
 
 
 
Figure 39: Cell tropism for MEF- or NIH-produced MCMV. 
This model proposes that MEF-derived (left) and NIH3T3-derived (right) MCMV contain different amounts of 
gH/gL/m74 and gH/gL/MCK-2 complexes, thus, show different infection capacities for different cell types. The 
strength of arrows represent the infection capacity. 
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4.9.3 How could the model be verified? 
MCMV encodes m74 and MCK-2 which are incorporated into different gH/gL complexes 
and serve as functional homologues to HCMV gH/gL/gO [165] and gH/gL/pUL(128, 130, 
131a), respectively [166]. Both the gH/gL/m74 and gH/gL/MCK-2 complexes function as 
MCMV entry mediators, and changes in the relative ratios of the two complexes in virions 
may affect the infection properties. To verify the above model, antibodies recognizing m74 
and MCK-2 are required to evaluate the abundancies of the MCMV gH/gL complexes in 
virions released from different cells. However, currently no m74-specific antibody is 
available. The next step would be to generate an anti-m74 antibody which will include 
cloning and expression of m74, and immunization of rabbits or mice. If differences are 
found or verified, this would support MCMV as a good model to study role of HCMV gH/gL 
complexes. 
 
 
4.10 Conclusion and perspectives 
In this work, PDGFRα has been identified as a binding partner for the HCMV gH/gL/gO 
complex by looking for protein binding partner of HCMV virions on the cell surface of 
fibroblasts. The surface expression levels of PDGFRα very likely determine the HCMV 
entry pathway. When HCMV infects cells with high level of PDGFRα, such as fibroblasts, 
infection is mainly driven by gH/gL/gO, whereas infection of cells expressing low level of 
PDGFRα, such as epithelial cells and EC, is mainly driven by gH/gL/pUL(128, 130, 131a). 
gH/gL/gO promotes entry of free virus through a PDGFRα-dependent pathway and cell-
associated virus spread through a PDGFRα-independent pathway. 
 
It has been shown that the gH/gL/m74 complex of MCMV determines virus entry into first 
target cells during primary MCMV infection of the mouse [109]. Transferred to HCMV 
infections in vivo, the gH/gL/gO-PDGFRα interaction may thus also play a pivotal role in 
primary HCMV infection. The gH/gL/gO-PDGFRα interaction, may determine horizontal 
dissemination via free virus in body fluids like breast milk or urine. This renders the 
gH/gL/gO-PDGFRα interaction a potential target for HCMV vaccines, new therapeutic 
avenues and facilitate screening of small-molecule antagonists to block HCMV entry during 
primary infections. Molecules targeting gO may become an important new group of 
potential antivirals. A number of antibodies, peptides and small compounds have been 
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shown to bind to PDGFRα. Alternatively, soluble PDGFRα, or peptides derived from 
PDGFRα may interfere with viral spread in an infected individual. Mapping of the gH/gL/gO-
PDGFRα interaction site would be very helpful in the design of future treatments of HCMV 
infection and disease. 
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6 Appendix 
 
6.1 List of abbreviation 
2-ME 2-mercaptoethanol 
3D three dimensional 
aa amino acids 
AIDS  acquired immune-deficiency syndrome 
APS ammonium persulfate 
BCA bicinchoninic acid 
BSA bovine serum albumin 
CCR CC chemokine receptor 
CD cluster of differentiation 
cDNA complementary DNA 
Co-IP Co-immunoprecipitation 
DMEM Dulbecco's modified Eagle medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxinucleosid-triphosphate 
dpi day(s) post infection 
DTT dithiothreitol 
EC endothelial cells 
ECL enhanced chemiluminescence 
EDTA ethylene diamine tetraacetic acid 
e.g. exempli gratia 
EGFR epidermal growth factor receptor 
ELISA enzyme-linked immunosorbent assay 
et al. et alii/alia 
EtBr ethidium bromide 
FACS fluorescence-activated cell sorter 
FBS fetal bovine serum 
FDA U S Food and Drug Administration 
FITC fluorescein isothiocyanate 
gB (H, L, M, N, O) glycoprotein (H, L, M, N, O) 
HA hemagglutinin 
HCMV human cytomegalovirus 
HEPES N-2-hydroxyethylpiperazine-N’-2 ethanesulfonic acid 
HFF human foreskin fibroblast 
HHV  human herpes virus 
HIV human immunodeficiency virus 
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h p.i. hour(s) post infection 
HRP horseradish peroxidase 
HSPGs heparan sulfate proteoglycans 
HSV herpes simplex virus 
IE immediate early 
IF immunofluorescence  
IFN interferon 
Ig immunoglobulin 
IL interleukin 
mAbs monoclonal antibodies 
MAPK mitogen-activated protein kinases 
MCMV murine cytomegalovirus 
MCP major capsid protein 
MEF murine embryonic fibroblasts 
MOI multiplicity of infection 
OD optical density 
ORF open reading frame 
PAA polyacrylamide gel electrophoresis 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PFA paraformaldehyde 
PFU plaque-forming unit 
PI3K phosphatidylinositol 3-kinases 
p.i. post infection 
RNA ribonucleic acid 
RT room temperature 
SDS sodium dodecyl sulfate 
SDS-PAGE SDS-Poly-acrylamid gel electrophoreses 
TAE Tris-Acetate-EDTA 
TEMED N,N,N’,N’ – Tetramethylethylendiamin 
VSV Vesicular stomatitis virus 
VZV Varicella zoster virus 
WT wildtype 
WB Western Blot 
Units 
°C Degree Celsius 
bp base pair 
Da Dalton 
g gram or gravitational constant 
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h hour (s) 
L liter 
M molar (mol/l) 
m meter 
min minute (s) 
pH pondus Hydrogenii 
rpm revolutions per minute 
sec Second 
V volt 
Prefixes 
k kilo 
m mini 
µ micro 
n nano 
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6.2 Publications and posters 
This thesis describes work performed at the Max von Pettenkofer-Institute, in Munich 
between October 2012 and November 2015. Parts of the study were published or 
presented at conferences. 
 
Publications 
1. Y Wu, A Prager, S Boos, M Resch, I Brizic, M Mach, S Wildner, L Scrivano, B Adler* 
“Human cytomegalovirus glycoprotein complex gH/gL/gO uses PDGFR-α as a key for 
entry” PLOS Pathogens, in revision  
 
2. N.A. Lemmermann, A. Krmpotic, J. Podlech, I. Brizic, A. Prager, H. Adler, A. Karbach, Y 
Wu, S. Jonjic, M.J. Reddehase, and B. Adler*. “Non-redundant and Redundant Roles of 
Cytomegalovirus gH/gL Complexes in Host Organ Entry and Intra-tissue Spread” PLoS 
Pathog. 2015; 11(2): e1004640 
 
Poster presentation 
Y Wu, I Brizic, L Scrivano, S Schuller, A Prager and B Adler* (2014) HCMV glycoprotein 
complex gH/gL/gO directly promotes virus entry into fibroblasts. 24th Annual Meeting of 
the Society for Virology, 2014, Alpbach, Austria 
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